Use: Labeled indications
- KEPPRA is indicated for the treatment of partial-onset seizures in patients 1 month of age and older
- Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy
- Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy
Full indications and usage US FDA label
1 INDICATIONS AND USAGE KEPPRA is indicated for the treatment of partial-onset seizures in patients 1 month of age and older (1.1) KEPPRA is indicated for adjunctive therapy for the treatment of: Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy (1.2) Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy (1.3) 1.1 Partial-Onset Seizures KEPPRA is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. 1.2 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy KEPPRA is indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. 1.3 Primary Generalized Tonic-Clonic Seizures KEPPRA is indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy.
Contraindications
- Hypersensitivity to levetiracetam
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS KEPPRA is contraindicated in patients with a hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema [see Warnings and Precautions (5.4)]. Known hypersensitivity to levetiracetam; angioedema and anaphylaxis have occurred (4, 5.4)
Dosing: Adult
- Partial-onset seizures (adults, 16 years and older): 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to 1,500 mg twice daily
- Myoclonic and primary generalized tonic-clonic seizures (adults): Same titration to 1,500 mg twice daily
- Use the oral solution for pediatric patients with body weight ≤ 20 kg (2.1)
- For pediatric patients, use weight-based dosing for the oral solution with a calibrated measuring device (not a household teaspoon or tablespoon) (2.1)
- Partial-Onset Seizures (monotherapy or adjunctive therapy) 1 Month to < 6 Months: 7 mg/kg twice daily; increase by 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily (2.2)
- 6 Months to < 4 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily (2.2)
- 4 Years to < 16 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily (2.2)
- Adults 16 Years and Older: 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to a recommended dose of 1500 mg twice daily (2.2)
- Myoclonic Seizures in Adults and Pediatric Patients 12 Years and Older 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily (2.3)
- Primary Generalized Tonic-Clonic Seizures 6 Years to < 16 Years: 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily (2.4)
- Adults 16 Years and Older: 500 mg twice daily, increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily (2.4)
- …
2.1 Important Administration Instructions
2.1 Important Administration Instructions KEPPRA is given orally with or without food. The KEPPRA dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function. Prescribe the oral solution for pediatric patients with body weight ≤ 20 kg. Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg.
When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon). KEPPRA tablets should be swallowed whole. KEPPRA tablets should not be chewed or crushed.
2.2 Dosing for Partial-Onset Seizures
2.2 Dosing for Partial-Onset Seizures The recommended dosing for monotherapy and adjunctive therapy is the same; as outlined below. Adults 16 Years of Age and Older Initiate treatment with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg.
There is no evidence that doses greater than 3000 mg/day confer additional benefit. Pediatric Patients 1 Month to < 6 Months Initiate treatment with a daily dose of 14 mg/kg in 2 divided doses (7 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 14 mg/kg to the recommended daily dose of 42 mg/kg (21 mg/kg twice daily).
In the clinical trial, the mean daily dose was 35 mg/kg in this age group. 6 Months to < 4 Years: Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose in 2 weeks by an increment of 20 mg/kg to the recommended daily dose of 50 mg/kg (25 mg/kg twice daily). If a patient cannot tolerate a daily dose of 50 mg/kg, the daily dose may be reduced.
In the clinical trial, the mean daily dose was 47 mg/kg in this age group. 4 Years to < 16 Years Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced.
In the clinical trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3000 mg/day. For KEPPRA tablet dosing in pediatric patients weighing 20 to 40 kg, initiate treatment with a daily dose of 500 mg given as twice daily dosing (250 mg twice daily). Increase the daily dose every 2 weeks by increments of 500 mg to a maximum recommended daily dose of 1500 mg (750 mg twice daily).
For KEPPRA tablet dosing in pediatric patients weighing more than 40 kg, initiate treatment with a daily dose of 1000 mg/day given as twice daily dosing (500 mg twice daily). Increase the daily dose every 2 weeks by increments of 1000 mg/day to a maximum recommended daily dose of 3000 mg (1500 mg twice daily). KEPPRA Oral Solution Weight-Based Dosing Calculation For Pediatric Patients The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients: Total daily dose (mL/day) = Daily dose (mg/kg/day) × patient weight (kg) ------------------------------------------------ 100 mg/mL
2.3 Dosing for Myoclonic Seizures in Patients 12 Years of Age and Older with Juvenile
2.3 Dosing for Myoclonic Seizures in Patients 12 Years of Age and Older with Juvenile Myoclonic Epilepsy Initiate treatment with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase the dosage by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.
2.4 Dosing for Primary Generalized Tonic-Clonic Seizures Adults 16 Years of Age and Older
2.4 Dosing for Primary Generalized Tonic-Clonic Seizures Adults 16 Years of Age and Older Initiate treatment with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase dosage by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.
Pediatric Patients 6 to <16 Years of Age Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied.
Patients with body weight ≤20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution [see Dosage and Administration (2.1)]. Only whole tablets should be administered.
2.5 Dosage Adjustments in Adult Patients with Renal Impairment
2.5 Dosage Adjustments in Adult Patients with Renal Impairment KEPPRA dosing must be individualized according to the patient's renal function status. Recommended dosage adjustments for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated.
To do this an estimate of the patient's creatinine clearance (CLcr) in mL/min must first be calculated using the following formula: CLcr= [140-age (years)] × weight (kg) ---------------------------------------- 72 × serum creatinine (mg/dL) (× 0.85 for female patients) Then CLcr is adjusted for body surface area (BSA) as follows: CLcr (mL/min/1.73 m² )= CLcr (mL/min) ------------------------------ BSA subject (m 2) × 1.73 Table 1: Dosing Adjustment Regimen for Adult Patients with Renal Impairment Group Creatinine Clearance (mL/min/1.73 m²) Dosage (mg) Frequency Normal > 80 500 to 1,500 Every 12 hours Mild 50 – 80 500 to 1,000 Every 12 hours Moderate 30 – 50 250 to 750 Every 12 hours Severe < 30 250 to 500 Every 12 hours ESRD patients using dialysis ---- 500 to 1,000 Following dialysis, a 250 to 500 mg supplemental dose is recommended. Every 24 hours
2.6 Discontinuation
2.6 Discontinuation of KEPPRA Avoid abrupt withdrawal from KEPPRA in order to reduce the risk of increased seizure frequency and status epilepticus [see Warnings and Precautions (5.8)].
Dosing: Altered kidney function
Levetiracetam is cleared mainly by the kidneys (66% unchanged). The US label reduces the dose by creatinine clearance adjusted for body surface area and, for dialysis patients, gives 500 to 1,000 mg every 24 hours plus a 250 to 500 mg supplement after each hemodialysis, which removes about 50% in 4 hours.
Kidney function measure: Label uses Cockcroft-Gault CrCl adjusted to body surface area (mL/min/1.73 m2): >80, 50–80, 30–50, <30, and ESRD on dialysis. Site bands keep this measure; label cut-offs inside a band are stated.
Show full dosing details
- CrCl ≥60 mL/min
- CrCl >80: 500 to 1,500 mg every 12 hours. CrCl 50–80: 500 to 1,000 mg every 12 hours (label Table 1).
- CrCl 30–59 mL/min
- CrCl 50–80: 500 to 1,000 mg every 12 hours. CrCl 30–50: 250 to 750 mg every 12 hours (label Table 1).
- CrCl 15–29 mL/min
- CrCl <30: 250 to 500 mg every 12 hours (label Table 1).
- CrCl <15 mL/min (not on dialysis)
- CrCl <30: 250 to 500 mg every 12 hours (label Table 1).
- Hemodialysis (intermittent)
- ESRD on dialysis: 500 to 1,000 mg every 24 hours, plus a 250 to 500 mg supplemental dose after each dialysis (label Table 1). About 50% removed in a 4-hour session.
- Peritoneal dialysis
- The label's ESRD-on-dialysis row (500 to 1,000 mg every 24 hours) does not separate PD from HD; the post-dialysis supplement is for hemodialysis. Applying the 24-hour dose to PD without a supplement is clinical extrapolation; specialist input.
- CRRT
- No data in label. Removed by dialysis, so CRRT likely clears it; specialist input and seizure monitoring.
- Dialyzable? Yes: about 50% of the body pool removed in a standard 4-hour hemodialysis (label 10.3, 12.3).
- Monitoring Kidney function (CrCl) to set the dose. Seizure control. Behavioral changes, mood, suicidal thinking; somnolence and coordination problems. Avoid abrupt withdrawal.
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Weight-based dose by age (label).
- eGFR 30–59
- The label's kidney dosing table is for adults only; no pediatric kidney dose is given. Clearance falls with CrCl, so reduce by clinical judgment with specialist input.
- eGFR 15–29
- No pediatric kidney dose in label. Specialist input.
- eGFR <15 (not on dialysis)
- No pediatric kidney dose in label. Specialist input.
- Hemodialysis (intermittent)
- No pediatric dialysis dose in label; dialyzable (supplement after HD likely needed). Specialist input.
- Peritoneal dialysis
- No data. Specialist input.
- CRRT
- No data. Specialist input.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
2.5 Dosage Adjustments in Adult Patients with Renal Impairment KEPPRA dosing must be individualized according to the patient's renal function status. Recommended dosage adjustments for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated.
To do this an estimate of the patient's creatinine clearance (CLcr) in mL/min must first be calculated using the following formula: CLcr= [140-age (years)] × weight (kg) ---------------------------------------- 72 × serum creatinine (mg/dL) (× 0.85 for female patients) Then CLcr is adjusted for body surface area (BSA) as follows: CLcr (mL/min/1.73 m² )= CLcr (mL/min) ------------------------------ BSA subject (m 2) × 1.73 Table 1: Dosing Adjustment Regimen for Adult Patients with Renal Impairment Group Creatinine Clearance (mL/min/1.73 m²) Dosage (mg) Frequency Normal > 80 500 to 1,500 Every 12 hours Mild 50 – 80 500 to 1,000 Every 12 hours Moderate 30 – 50 250 to 750 Every 12 hours Severe < 30 250 to 500 Every 12 hours ESRD patients using dialysis ---- 500 to 1,000 Following dialysis, a 250 to 500 mg supplemental dose is recommended. Every 24 hours
8.6 Renal Impairment Clearance of levetiracetam is decreased in patients with renal impairment and is correlated with creatinine clearance [see Clinical Pharmacology (12.3)]. Dose adjustment is recommended for patients with impaired renal function and supplemental doses should be given to patients after dialysis [see Dosage and Administration (2.5)].
Renal Impairment The disposition of levetiracetam was studied in adult subjects with varying degrees of renal function. Total body clearance of levetiracetam is reduced in patients with impaired renal function by 40% in the mild group (CLcr = 50-80 mL/min), 50% in the moderate group (CLcr = 30-50 mL/min) and 60% in the severe renal impairment group (CLcr <30 mL/min).
Clearance of levetiracetam is correlated with creatinine clearance. In anuric (end stage renal disease) patients, the total body clearance decreased 70% compared to normal subjects (CLcr >80 mL/min). Approximately 50% of the pool of levetiracetam in the body is removed during a standard 4- hour hemodialysis procedure [see Dosage and Administration (2.5)].
Dosing: Pediatric
- Approved ages
- Partial-onset seizures from 1 month; myoclonic seizures 12 years and older; primary generalized tonic-clonic seizures 6 years and older (label).
- Usual dose
- Partial-onset: 1 to <6 months, 7 mg/kg twice daily up to 21 mg/kg twice daily; 6 months to <4 years, 10 up to 25 mg/kg twice daily; 4 to <16 years, 10 up to 30 mg/kg twice daily (label 2.2).
- Maximum dose
- 30 mg/kg twice daily (4 to <16 years); do not exceed adult maximum 3,000 mg/day.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of KEPPRA for the treatment of partial-onset seizures in patients 1 month to 16 years of age have been established [see Clinical Pharmacology (12.3) and Clinical Studies (14.1)]. The dosing recommendation in these pediatric patients varies according to age group and is weight-based [see Dosage and Administration (2.2)].
The safety and effectiveness of KEPPRA as adjunctive therapy for the treatment of myoclonic seizures in adolescents 12 years of age and older with juvenile myoclonic epilepsy have been established [see Clinical Studies (14.2)]. The safety and effectiveness of KEPPRA as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in pediatric patients 6 years of age and older with idiopathic generalized epilepsy have been established [see Clinical Studies (14.3)].
Safety and effectiveness for the treatment of partial-onset seizures in pediatric patients below the age of 1 month; adjunctive therapy for the treatment of myoclonic seizures in pediatric patients below the age of 12 years; and adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in pediatric patients below the age of 6 years have not been established. A 3-month, randomized, double-blind, placebo-controlled study was performed to assess the neurocognitive and behavioral effects of KEPPRA as adjunctive therapy in 98 (KEPPRA N=64, placebo N=34) pediatric patients, ages 4 to 16 years old, with partial seizures that were inadequately controlled.
The target dose was 60 mg/kg/day. Neurocognitive effects were measured by the Leiter-R Attention and Memory (AM) Battery, which measures various aspects of a child's memory and attention. Although no substantive differences were observed between the placebo and drug treated groups in the median change from baseline in this battery, the study was not adequate to assess formal statistical non-inferiority of the drug and placebo.
The Achenbach Child Behavior Checklist (CBCL/6-18), a standardized validated tool used to assess a child's competencies and behavioral/emotional problems, was also assessed in this study. An analysis of the CBCL/6-18 indicated on average a worsening in KEPPRA-treated patients in aggressive behavior, one of the eight syndrome scores [see Warnings and Precautions (5.1)].
Juvenile Animal Toxicity Data Studies of levetiracetam in juvenile rats (dosed on postnatal days 4 through 52) and dogs (dosed from postnatal weeks 3 through 7) at doses of up to 1800 mg/kg/day (approximately 7 and 24 times, respectively, the maximum recommended pediatric dose of 60 mg/kg/day on a mg/m 2 basis) did not demonstrate adverse effects on postnatal development.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use There were 347 subjects in clinical studies of KEPPRA that were 65 and over. No overall differences in safety were observed between these subjects and younger subjects. There were insufficient numbers of elderly subjects in controlled trials of epilepsy to adequately assess the effectiveness of KEPPRA in these patients.
Levetiracetam is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Clinical Pharmacology (12.3)].
Administration
2.1 Important Administration Instructions KEPPRA is given orally with or without food. The KEPPRA dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function. Prescribe the oral solution for pediatric patients with body weight ≤ 20 kg. Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg. When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon). KEPPRA tablets should be swallowed whole. KEPPRA tablets should not be chewed or crushed.
US FDA labelDosage forms
Philippines
- Film-coated tablet: 1 g, 250 mg, 500 mg, 750 mg, 1000 mg
- Oral solution: 100 mg/mL
- ) solution for injection: 100 mg/mL (500 mg/5 mL, 100 mg/mL (500 mg/mL
- ) concentrated solution for injection: 100 mg/mL (500 mg/5 mL
- Tablet: 250 mg, 500 mg
- Concentrate solution for injection: 100 mg/mL
- Concentrate for solution for iv infusion: 100 mg/mL, 500 mg/5 mL
- Solution for injection: 100 mg/mL
- Syrup: 100 mg/mL
- ) concentrate for solution for iv infusion: 100 mg/mL (500 mg/5 mL
and 10 more forms; see the products table.
Registered products in the Philippines
214 products registered with the Food and Drug Administration (FDA) Philippines list Levetiracetam as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products214
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Akucetam-1000Levetiracetam | 1 g Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4584 | Aug 5, 2028 | |
Akucetam-500Levetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4583 | Aug 5, 2028 | |
AlevraLevetiracetam | 250 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | Synmosa Biopharma Philippines, Inc.Importer: Medethix, Inc. | DRP-13283-02 | Feb 2, 2028 | |
AsynlevLevetiracetam | 500 mg Film-Coated TabletAlu / Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | Synmosa Biopharma Philippines Inc.Importer: MedEthix, Inc. | DRP-13281-01 | Feb 2, 2028 | |
Ceaser 1000Levetiracetam | 1 g Film-Coated TabletOpaque White Alu- PVC/PE/PVDC Blister Pack x 15's (Box of 60's) | Rx | Pharmathen SAGreece | Saifen Drugs Philippines, Inc. | DR-XY49155 | Aug 1, 2029 | |
Ceaser 1000Levetiracetam | 1 g Film-Coated TabletOpaque White Alu-PVC/ PE/ PVDC Blister Pack x 15's (Box of 60’s) | Rx | Pharmathen SAGreece | Saifen Drugs Philippines, Inc. | DRP-15815 | Aug 1, 2029 | |
Ceaser 500Levetiracetam | 500 mg Film-Coated TabletPVC/PE/PVDC Blister Pack x 10’s (Box of 60’s) | Rx | PHARMATHEN S.A.Greece | Saifen Drugs Philippines Inc. | DR-XY49792 | Sep 16, 2031 | |
CetaferLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Ferma Drug Enterprises | DRP-16434-04 | Mar 11, 2027 | |
CetanervLevetiracetam | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's(Box of 30's) | Rx | Zhejiang Jingxin Pharmaceutical Co. Ltd.China | Hexagon Pharmaceuticals | DRP-16334 | Feb 7, 2030 | |
CzureLevetiracetam | 250 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13518-01 | Mar 3, 2028 | |
CzureLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13517-01 | Mar 3, 2028 | |
DevetamLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Diafarm Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4583-08 | Aug 5, 2028 | |
Devetam 1000Levetiracetam | 1 g Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Diafarm Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4584-02 | Aug 5, 2028 | |
DretacenLevetiracetam | 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 60's) | Rx | Lek Pharmaceuticals D.D.Slovenia | Sandoz Philippines Corporation | DRP-5280 | Apr 23, 2029 | |
DretacenLevetiracetam | 250 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 60's) | Rx | Lek Pharmaceuticlas D.D.Slovenia | Sandoz Philippines Corporation | DRP-7486 | Feb 13, 2029 | |
DretacenLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 60's) | Rx | Lek Pharmaceuticals D.D.Slovenia | Sandoz Philippines Corporation | DRP-7484 | Feb 13, 2029 | |
DretazureLevetiracetam | 100 mg/mL SyrupAmber colored PET Bottle x 100 mL (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant II)India | Diafarm Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4984-02 | Dec 11, 2028 | |
EpcetamLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13517-05 | Mar 3, 2028 | |
EpileptLevetiracetam | 500mg/5mL Concentrate For Solution For Infusion5 mL USP Type I Flint vial sealed with 20 mm grey bromo butyl rubber stopper and aluminum with blue flip - off seal (Box of 10's) | Rx | Maiva Pharma Pvt. Ltd.India | Medethix, Inc.Trader: Adi Solutions Pty. Ltd. | DR-XY47953 | Apr 21, 2027 | |
EpilozLevetiracetam | 100mg/mL (500mg/5mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Red Bromobutyl Rubber Stopper and Blue Flip-off Cap x 5mL (Box of 10's) | Rx | Aroma Ilac San. LTD. STITurkey | Central West Medicale Inc.Importer: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac, San. Ve Tic. A.S. | DRP-10900-05 | Dec 14, 2026 | |
EpivraLevetiracetam | 100 mg/mL (500 mg/5 mL) Concentrate For Solution For IV InfusionUSP Type I clear glass vial x 5 mL (net content) with grey bromobutyl rubber stopper, aluminum seal, and blue flip-off cap (Box of 10's & 25's) | Rx | Kwality Pharmaceuticals Ltd.India | Pharma-Surrey International, Inc. | DRP-17876 | Mar 30, 2031 | |
EpsytamLevetiracetam | 500mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 60's) Box of 60's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DRP-15237 | Dec 19, 2028 | |
EterloxLevetiracetam | 500 mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 20's) | Rx | PT. Novell Pharmaceutical LaboratoriesIndonesia | Prosweal Healthcare Inc. | DR-XY49619 | Feb 3, 2031 | |
EtiraxinLevetiracetam | 100 mg / mL Oral SolutionBoston Round Amber Glass Bottle x 300 mL (Box of 1's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-16898-01 | Aug 11, 2030 | |
Exppra 500Levetiracetam | 500 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 30's) | Rx | Exemed PharmaceuticalsIndia | Saifen Drugs Philippines, Inc. | DR-XY49156 | Aug 1, 2029 | |
Exppra 500Levetiracetam | 500 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Saifen Drugs Philippines, Inc. | DRP-15773 | Aug 1, 2029 | |
FlexivateLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Ambitech Biopharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4583-11 | Aug 5, 2028 | |
FocaleLevetiracetam | 1 g Film-coated TabletAlu/Clear PVC/PVdC/PVC blister pack x 10's (Box of 30's) | Rx | Atlantic Pharma - Producoes Farmaceuticas, S.A.Portugal | UNILAB, Inc. | DR-XY46340 | May 11, 2028 | |
FocaleLevetiracetam | 100mg/mL Oral Solution200 mL Type III amber glass bottle with child-resistant plastic cap x 150 mL + 3 mL-capacity PP oral dosing syringe (Box of 1's) | Rx | Hetero Labs Limited (Unit III)India | Unilab, Inc.Importer: Camber Pharmaceuticals, Inc. | DRP-9033-06 | Aug 20, 2031 | |
FocaleLevetiracetam | 250 mg Film-coated TabletAlu/Clear PVC/PVdC/PVC blister pack x 10's (Box of 30's) | Rx | Atlantic Pharma - Producoes Farmaceuticas, S.A.Portugal | UNILAB, Inc. | DR-XY46338 | May 11, 2028 | |
FocaleLevetiracetam | 500 mg / 5 mL Concentrate for Solution for IV InfusionType I Clear Glass Vial with bromobutyl rubber stopper and aluminum flip-off cap x 5 mL (Box of 10's) | Rx | Pharmathen SAGreece | UNILAB, Inc. | DRP-12365 | Jul 26, 2027 | |
FocaleLevetiracetam | 500 mg Film-coated TabletAlu/Clear PVC/PVdC/PVC Blister Pack x 10's (Box of 30's | Rx | Atlantic Pharma - Producoes Farmaceuticas, S.A.Portugal | UNILAB, Inc. | DR-XY46339 | May 11, 2028 | |
GentracetLevetiracetam | 100 mg /mL (500 mg/ 5 mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Red Bromobutyl Rubber Stopper and Blue Flip-off Cap x 5 mL (Box of 2's, 4's, and 10's) | Rx | Aroma İlaç San. Ltd. ŞtiTurkey | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical, Inc.Trader: Polifarma İlaç San. Ve Tic. A.S. | DRP-10900-06 | Dec 14, 2026 | |
GocetamLevetiracetam | 500mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Acme Formulation Pvt. Ltd.India | Applied Pharmaceutical Distribution IncImporter: Medinova Pharmaceutical Inc. | DRP-10808-01 | Nov 25, 2026 | |
Golevet IVLevetiracetam | 100mg/mL (500mg/5mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glasss Vial with Red Bromobutyl Rubber Stopper and Blue Flip-off Cap x 5mL (Box of 10's) | Rx | Aroma Ilac San. Ltd. StiTurkey | Go Healthcare Pharmaceutical DistributionImporter: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac, San. Ve Tic. A.S. | DRP-10900-02 | Dec 14, 2026 | |
GolyptinLevetiracetam | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's; Box of 60's) | Rx | Zhejiang Jingxin Pharmaceutical Co. Ltd.China | Applied Pharmaceutical Distribution IncImporter: Medinova Pharmaceutical Inc. | DRP-13585-03 | Mar 14, 2028 | |
Ivetra 1000Levetiracetam | 1 g Film-Coated TabletAlu/PVC/PVDC Blister Pack X 10's (Box of 60's) | Rx | TORRENT PHARMACEUTICALS, LTD.India | TORRENT PHARMA PHILIPPINES, INC. | DRP-2410 | Oct 14, 2029 | |
Ivetra 250Levetiracetam | 250 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 60's) | Rx | Torrent Pharmaceuticals Ltd.India | Importer: Torrent Pharma Philippines Inc. | DRP-2408 | Jan 22, 2030 | |
IVETRA 500Levetiracetam | 500 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 60's) | Rx | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DRP-2409 | Oct 15, 2029 | |
Ivetra IVLevetiracetam | 100 mg/ mL (500 mg/5mL) Solution for Injection (IV)USP Type I Glass Vial Sealed with 20 mm Grey Rubber Stopper and Blue Aluminum Flip-off Seal x 5 mL (Box of 1's) | Rx | Aspiro Pharma LimitedIndia | Torrent Pharma Philippines Inc.Importer: Camber Pharmaceuticals, Inc. | DRP-9232-01 | Jul 6, 2031 | |
Ivetra IVLevetiracetam | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Borosilicate Glass Vial with Gray Rubber Stopper and Aluminum Plastic Overseal Cap x 10 mL (Box of 1’s) | Rx | Hainan Poly Pharm. Co., Ltd.China | Torrent Pharma Philippines, Inc.Importer: Ambica International Corporation | DRP-11179-02 | Feb 10, 2027 | |
Ivetra-100Levetiracetam | 100 mg /mL Oral Solution200 mL Type III amber glass bottle with child-resistant plastic cap x 150 mL + 3 mL-capacity pp oral dosing syringe (Box of 1's) | Rx | Hetero Labs Limited (Unit III)India | Torrent Pharma Philippines, Inc.Importer: Camber Pharmaceuticals, inc. | DRP-9033-01 | Jun 9, 2031 | |
JulitamLevetiracetam | 100 mg/mL Oral Solution200 mL Type III amber glass bottle with child–resistant plastic cap x 150 mL + 3 mL - capacity PP oral dosing syringe (Box of 1’s) | Rx | Hetero Labs LimitedIndia | Zydus Healthcare Philippines Inc.Importer: Camber Pharmaceuticals, Inc. | DRP-9033-05 | Jul 15, 2031 | |
Julitam 1000Levetiracetam | 1 g Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 100's) | Rx | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-7351 | Dec 18, 2028 | |
Julitam 250Levetiracetam | 250 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 100's); Alu/PVDC Blister Pack x 10's As physician's sample: Box of 10's | Rx | Cadila Healthcare Ltd.India | Zydus Healthcare Philippines, Inc. | DRP-7576 | Dec 18, 2028 | |
Julitam 500Levetiracetam | 500 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's Box of 100's | Rx | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-7322 | Dec 18, 2028 | |
Julitam 750Levetiracetam | 750 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 100's) | Rx | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-7350 | Dec 18, 2028 | |
Julitam I.V.Levetiracetam | 100 mg/mL Concentrate Solution for Injection (IV Infusion)Type I Clear Colorless Flint Ampoule x 5 mL in Plastic Tray (Box of 1’s) | Rx | Troikaa Pharmaceuticals LimitedIndia | Zydus Healthcare Philippines Inc.Importer: Troikaa Pharmaceuticals Philippines, Inc. | DRP-15623-01 | May 21, 2030 | |
Julitam I.V.Levetiracetam | 100mg/mL (500mg/5mL)Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Red Bromobutyl Rubber Stopper and Blue Flip-off Cap x 5mL (Box of 10's) | Rx | Aroma Ilac San. Ltd. StiTurkey | Zydus Healthcare Philippines Inc.Importer: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac San. Ve Tic. A.S. | DRP-10900-01 | Dec 14, 2026 | |
JuvicetLevetiracetam | 100 mg/mL (500 mg/5 mL) Concentrate Solution for Injection (1.V. Infusion)Clear USP Type I glass vial x 5 mL closed with a gray bromobutyl rubber stopper and blue flip-off seal (Box of 1’s) | Rx | Ciron Drugs & Pharmaceuticals Pvt. LimitedIndia | Phil Pharmawealth, Inc.Trader: Oboi Laboratories | DR-XY49533 | Oct 2, 2030 | |
KepdinLevetiracetam | 100 mg/mL Oral Solution300 mL Wide Mouth Boston Round Amber Bottle (Box of l’s) | Rx | Lifesquare Laboratories Inc.Philippines | Trader: Medchoice CNS Pharma Corporation | DRP-12346 | Jul 21, 2027 | |
KepdinLevetiracetam | 250 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Medchoice CNS Pharma CorporationImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4585-01 | Aug 5, 2028 | |
KepdinLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Medchoice CNS Pharma CorporationImporter: Pharmakon Biotec Inc. | DRP-13517-3 | Mar 3, 2028 | |
KepdinLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Medchoice CNS Pharma CorporationImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4583-01 | Aug 5, 2028 | |
Kepdin SyrupLevetiracetam | 100 mg/mL SyrupAmber Colored PET Bottle x 100 mL (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant II)India | Medchoice CNS Pharma CorporationImporter: Ambica International CorporationTrader: Unosource Pharma Limited | DRP-4984 | Dec 11, 2028 | |
KeppraLevetiracetam | 1 g Film-Coated TabletBlister Pack of 10's (Box of 60's) | Rx | UCB Pharma SABelgium | Importer: GlaxoSmithKline Philippines Inc. | DR-XY29122 | Mar 4, 2028 | |
KeppraLevetiracetam | 100 mg/mL Oral SolutionUSP Type III Amber Glass Bottle with white polypropylene child-resistant closure system x 300 mL (Box of 1's) | Rx | Next Pharma SAS - LimayFrance | Importer: GlaxoSmithKline Philippines Inc. | DR-XY34709 | Jul 10, 2028 | |
KeppraLevetiracetam | 250 mg Film-coated TabletAlu/PVC Blister Pack x 10's (Box of 60's) | Rx | UCB Pharma SABelgium | Importer: GlaxoSmithKline Philippines Inc. | DR-XY29934 | Nov 20, 2027 | |
KeppraLevetiracetam | 500 mg Film-Coated TabletBlister Pack of 10's (Box of 60's) | Rx | UCB Pharma SABelgium | Importer: GlaxoSmithKline Philippines, Inc. | DR-XY29131 | Mar 4, 2028 | |
KeppraLevetiracetam | 500 mg/5 mL Concentrate for Solution for IV InfusionType I clear and colorless glass vial x 5 mL with orange flip-off seal in a plastic tray x 5's (Box of 10's) | Rx | Patheon Italia S.p.A.Italy | Importer: GlaxoSmithKline Philippines, Inc. | DR-XY36632 | Sep 10, 2029 | |
KepreptolLevetiracetam | 500 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 60's) | Rx | WhanIn Pharm. Co., Ltd.Republic of Korea | Bell-Kenz Pharma Inc.Importer: JLT Pharma Inc. | DRP-8354 | Sep 3, 2029 | |
KlevraLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 90's) | Rx | PharmEvo (Pvt.) Ltd.Pakistan | Accesspoint International Trading Inc. | DRP-4816 | Oct 14, 2028 | |
LeavurLevetiracetam | 1 g Film-coated TabletPVC/PE/PVDC/Alu Triple Laminated Clear Blister Foil x 10's (Box of 30's) | Rx | Aurobindo Pharma Limited, Formulation Unit - XVIndia | AAA Pharma, Inc. | DRP-16780 | Jul 10, 2030 | |
LeavurLevetiracetam | 500 mg Film Coated TabletPVC/PE/PVDC/Alu Triple Laminated Clear Blister Foil x 10's (Box of 30's) | Rx | Aurobindo Pharma Limited, Formulation Unit - XVIndia | AAA Pharma, Inc. | DRP-16824 | Jul 21, 2030 | |
Leciteram 1000Levetiracetam | 1g Film-Coated TabletAlu-Clear PVC/PVDC Blister Pack x 10's (Box of 60's and 100's) | Rx | SunGlow Lifescience Private Limited.India | Despina Pharma Inc. | DRP-16132 | Nov 7, 2029 | |
Leciteram 250Levetiracetam | 250 mg Film-Coated TabletAlu-Clear PVC/PVDC Blister Pack x 10's (Box of 60's and 100's) | Rx | SunGlow Lifesciences Private LimitedIndia | Despina Pharma Inc. | DRP-16134 | Nov 7, 2029 | |
Leciteram 500Levetiracetam | 500 mg Film-Coated TabletAlu-Clear PVC/PVDC Blister Pack x 10's (Box of 60's and 100's) | Rx | SunGlow Lifescience Private LimitedIndia | Despina Pharma Inc. | DRP-16133 | Nov 7, 2029 | |
LecitramLevetiracetam | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV Infusion)5 mL USP Type I Clear Transparent Glass Vial along with Grey Bromobutyl Rubber Stopper and Orange Aluminum Flip-off Seal (Box of 25's) | Rx | Gland Pharma LimitedIndia | Pharma-Surrey International, Inc. | DRP-9579 | Mar 5, 2031 | |
LentiraLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | The Cathay YSS Distributors Co., Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4583-02 | Aug 5, 2028 | |
Lepiva 250Levetiracetam | 250 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Ambitech Biopharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4585-03 | Aug 5, 2028 | |
Lepiva-500Levetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Ambitech Biopharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4583-04 | Aug 5, 2028 | |
LepixaLevetiracetam | 100 mg/mL (500 mg/5mL) Solution for Injection (IV)USP Type I glass vial sealed with 20 mm grey rubber stopper and blue aluminum flip-off seal x 5 mL (Box of 1's) | Rx | Aspiro Pharma LimitedIndia | Emcure Pharma PhilippinesImporter: Camber Pharmaceuticals Inc | DRP-9232-03 | Oct 31, 2031 | |
LepixaLevetiracetam | 100 mg/mL Oral SolutionType III Amber Glass Bottle with Child-Resistant Plastic Cap x 200 mL + 3 mL-Capacity Polypropylene Oral Dosing Syringe (Box of 1's) | Rx | Hetero Labs Limited (Unit Iii)India | Emcure Pharma Philippines Inc.Importer: Camber Pharmaceuticals, Inc. | DRP-9033-03 | Jul 30, 2031 | |
Lepixa 1000Levetiracetam | 1 g Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Hetero Labs Limited (Unit III)India | Emcure Pharma PhilippinesImporter: Camber Pharmaceuticals Inc | DRP-6433-01 | Oct 31, 2031 | |
Lepixa 500Levetiracetam | 500 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 100's) | Rx | Hetero Labs LimitedIndia | Emcure Pharma Philippines Inc.Importer: Camber Pharmaceuticals, Inc. | DRP-6432-02 | Nov 30, 2027 | |
LepmedLevetiracetam | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's; Box of 60's) | Rx | Zhejiang Jingxin Pharmaceutical Co. Ltd.China | Blue Medceuticals Marketing Corp.Importer: Medinova Pharmaceutical Inc. | DRP-13585-04 | Mar 14, 2028 | |
LepstopLevetiracetam | 100 mg/mL (500 mg/5 mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Red Bromobutyl Rubber Stopper and Blue Flip-Off Cap x 5 mL (Box of 10's) | Rx | Aroma İlaç San. Ltd.Turkey | Importer: Medinova Pharmaceutical, Inc. | DRP-10900 | Dec 14, 2026 | |
LeptamLevetiracetam | 100 mg/mL (500mg/5mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Red Bromobutyl Rubber Stopper and Blue Flip-off Cap x 5ml (Box of 10's) | Rx | Aroma Ilac San. Ltd. StiTurkey | Tamiga Pharmaceuticals SupplyImporter: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac, San. Ve Tic. A.S. | DRP-10900-03 | Dec 14, 2026 | |
Leptam TabLevetiracetam | 500 mg Film-Coated TabletAlu/ PVC Blister Pack x 10's (Box of 30's) | Rx | Zhejiang Jingxin Pharmaceutical Co. Ltd.China | Tamiga Pharmaceuticals SupplyImporter: Medinova Pharmaceutical Inc. | DRP-13585-02 | Mar 14, 2028 | |
Leteram-250Levetiracetam | 250 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Diafarm Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4585-04 | Aug 5, 2028 | |
Leteram-500Levetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4583-06 | Aug 5, 2028 | |
LetramLevetiracetam | 250 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's Box of 100's | Rx | Hetero Labs LimitedIndia | Camber Pharmaceuticals, Inc. | DRP-6431 | Nov 30, 2027 | |
LetramLevetiracetam | 500 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's Box of 100's | Rx | Hetero Labs LimitedIndia | Camber Pharmaceuticals, Inc. | DRP-6432 | Nov 30, 2027 | |
LevacetamLevetiracetam | 100 mg/mL (500 mg/5 mL) Concentrated Solution for Injection ( IM/IV)5mL USP Type I Clear Glass Vial along with Grey Bromobutyl Rubber Stopper and White Alumimun Flip -Off Seal x 10's (Box of 10's) | Rx | Micro Labs LimitedIndia | Brown & Burk Philippines Inc. | DRP-11425 | May 11, 2031 | |
LevacetamLevetiracetam | 500 mg Film Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | Rx | Micro Labs LimitedIndia | Brown & Burk Philippines Inc.Importer: OEP Philippines Inc. | DRP-7248-01 | Jul 6, 2031 | |
LevcetamLevetiracetam | 500 mg/5 mL Solution For I.V. Infusion5 mL USP Type I clear transparent glass vial with gray Bromobutyl rubber stopper & light-blue colour flip-off seal - (Box of 1's & 10's) | Rx | Anhil Parenteral Pvt. Ltd.India | Biophil Medical Equipment and Supplies Trading | DRP-18439 | Jul 10, 2031 | |
LevecareLevetiracetam | 500 mg Film-Coated TabletAlu-PVDC Blister pack x 10's (Box of 100's) | Rx | Hetero Labs Limited (Unit III)India | Multicare Pharmaceuticals Phils. Inc.Importer: Camber Pharmaceuticals, Inc. | DRP-6432-03 | Nov 30, 2027 | |
LevecetamLevetiracetam | 100mg/mL Solution for Injection (IV)Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Green Aluminum Flip-Off Seal Cap x 5mL (Box of 1's) | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-16961 | Sep 2, 2030 | |
LevegetLevetiracetam | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)5 mL USP Type I Clear Glass Ampoule (Box of 1's) | Rx | Getz Pharma Pvt. Ltd.Pakistan | Getz Pharma (Phils.), Inc. | DR-XY47793 | Mar 10, 2027 | |
LevegetLevetiracetam | 1g Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's); and Alu/PVC Blister Pack x 1's (Box of 1's) as Physician Sample | Rx | Getz Pharma Pvt. Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | DR-XY47434 | Feb 21, 2028 | |
LevegetLevetiracetam | 250mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's) | Rx | Getz Pharma Pvt. Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | DR-XY47432 | Mar 6, 2028 | |
LevegetLevetiracetam | 500mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's); and Alu/PVC Blister Pack x 1's (Box of 1's) as Physician Sample | Rx | Getz Pharma Pvt. Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | DR-XY47433 | Feb 21, 2028 | |
LevegetLevetiracetam | 750mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's); and Alu/PVC Blister Pack x 1's (Box of 1's) as Physician Sample | Rx | Getz Pharma Pvt. Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | DR-XY47689 | Feb 21, 2028 | |
LevelepticLevetiracetam | 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | Medethix, Inc. | DRP-16432 | Sep 11, 2030 | |
LevelepticLevetiracetam | 250mg Film-Coated TabletAlu/Alu Blister pack x 10's | Rx | — | — | DRP-13283 | Feb 2, 2028 | |
LevelepticLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | MedEthix, Inc. | DRP-13281 | Feb 2, 2028 | |
LevelifeLevetiracetam | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 1’s (Box of 1’s) as Physician’s Sample; Alu/PVC Blister Pack x 10’s (Box of 10’s, 30’s, 60’s and 100’s) | Rx | Galen Pharmaceuticals LimitedIndia | Biophil Medical Equipment and Supplies Trading | DRP-18763 | Sep 1, 2031 | |
Levellen-PE500Levetiracetam | 100mg/mL Concentrated Solution For Iv Infusion5 mL USP Type I clear glass vial, with grey bromobutyl rubber stopper, aluminum seal, and blue flip-off cap (Box of 1's and 10's) | Rx | Penam Biosciences Pvt. Ltd.India | Ollen Pharma Trading Inc. | DRP-18898 | Sep 29, 2031 | |
Levensa IVLevetiracetam | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)5 mL-capacity Type I Clear Glass Vial Sealed with Gray Chlorobutyl Rubber Stopper and Aluminum Seal with Pink Flip-off Cap x 1's (Box of 1's and 10's) | Rx | Able Medical Company LimitedThailand | Euro-Care Product Philippines | DRP-18993 | Oct 14, 2031 | |
LevephaseLevetiracetam | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Borosilicate Glass Vial with Gray Rubber Stopper and Aluminum Plastic Overseal Cap x 10 mL (Box of 1’s and 10’s) | Rx | Hainan Poly Pharm. Co., Ltd.China | Ambica International Corporation | DRP-11179 | Feb 10, 2032 | |
LeveragenLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-16434-02 | Mar 11, 2027 | |
LeveramLevetiracetam | 1 g Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Intas Pharmaceuticals LimitedIndia | Endure Medical, Inc.Importer: Singapore Genebio, Inc. | DRP-7514 | Nov 21, 2027 | |
LeveramLevetiracetam | 250 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Intas Pharmaceuticals LimitedIndia | Endure Medical, Inc.Importer: Singapore Genebio, Inc. | DRP-7678 | Nov 21, 2027 | |
LeveramLevetiracetam | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Intas Pharmaceuticals LimitedIndia | Endure Medical, Inc.Importer: Singapore Genebio, Inc. | DRP-7679 | Nov 21, 2027 | |
LEVERAPLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-16434-01 | Mar 11, 2027 | |
LeveroLevetiracetam | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)USP Type I glass vial sealed with 20 mm grey rubber stopper and blue aluminum flip-off seal x 5 mL (Box of 1's) | Rx | Aspiro Pharma LimitedIndia | Camber Pharmaceuticals, Inc | DRP-9232 | Nov 9, 2031 | |
LevesaphLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-12687 | Jul 31, 2030 | |
LevestalLevetiracetam | 100 mg/mL Oral SolutionUSP Type III Amber colored glass bottle with child resistant polypropylene cap x 300 mL (Box of 1's) | Rx | Stallion Laboratories Pvt. LtdIndia | Ambica International Corporation | DRP-17823 | Mar 17, 2031 | |
Levestal-500Levetiracetam | 500 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Kodapharm Med Corp.Importer: Ambica International Corporation | DRP-10907 | Dec 23, 2031 | |
LevesyncLevetiracetam | 100 mg / mL Oral SolutionBoston Round Amber Glass Bottle x 300 mL (Box of 1's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Starpharm, Inc. | DRP-16898-02 | Aug 11, 2030 | |
Levetigrand 250Levetiracetam | 250 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. LtdIndia | Grandis Pharma IncorporatedImporter: Pharmakon Biotec Inc. | DRP-13518-02 | Mar 3, 2028 | |
Levetigrand 500Levetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Grandis Pharma IncorporatedImporter: Pharmakon Biotec Inc. | DRP-13517-02 | Mar 3, 2028 | |
Levetirasaph-AltLevetiracetam | 100 mg/mL Concentrated Solution For Iv Infusion5 mL USP Type I clear glass vial, with grey bromobutyl rubber stopper, aluminum seal, and blue flip-off cap (Box of 1's and 10's) | Rx | Althea Phama Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-18899 | Sep 29, 2031 | |
LevetraLevetiracetam | 500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 60's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Vitalink Health Products, Inc. | DR-XY43111 | Dec 19, 2028 | |
Levetramed - 1000Levetiracetam | 1 g Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Zhejiang Jingxin Pharmaceutical Co. Ltd.China | Medinova Pharmaceutical Inc. | DRP-13584 | Mar 14, 2028 | |
Levetramed - 500Levetiracetam | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Zhejiang Jingxin Pharmaceutical Co. Ltd.China | Medinova Pharmaceutical Inc. | DRP-13585 | Mar 14, 2028 | |
LevetrexLevetiracetam | 1000mg Film Coated TabletAlu-PVC Blister Pack x 10's | Rx | Globela Pharma Private LimitedIndia | AMB HK Enterprises, Inc. | DRP-19113 | Oct 29, 2031 | |
LevetrexLevetiracetam | 250mg Film Coated TabletAlu/PVC blister pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-14241 | Aug 2, 2028 | |
LevetrexLevetiracetam | 500mg Film Coated TabletAlu/PVC blister pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-14242 | Aug 2, 2028 | |
LevetricareLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Medcare PharmaceuticalsImporter: Pharmakon Biotec, Inc. | DRP-13517-07 | Mar 3, 2028 | |
LevetroyLevetiracetam | 100 mg / mL Concentrate Solution for Injection (IV Infusion)Type I Clear Colorless Flint Ampoule x 5mL in Plastic Tray (Box of 10's) | Rx | Troikaa Pharmaceuticals LimitedIndia | Troikaa Phramaceuticals Philippines, Inc. | DRP-15623 | Jun 4, 2029 | |
LevetroyLevetiracetam | 100 mg/mL Concentrate Solution for Injection (IV Infusion)5 mL Clear Glass Vial (Ph.Eur. Type I) with 20 mm Bromobutyl Rubber Stopper and 20 mm White Flip off Seal (Box of 1's) | Rx | Troikaa Pharmaceuticals LimitedIndia | Troikaa Pharmaceuticals Philippines Inc. | DR-XY49106 | May 21, 2030 | |
LevetroyLevetiracetam | 100mg/mL Concentrate Solution for Injection (IV Infusion)5mL Clear Glass Vial (Ph. Eur. Type I) with 20mm Bromobutyl Rubber Stopper anad 20mm White Flip Off Seal (Box of 1's) | Rx | Troikaa Pharmaceuticals LimitedIndia | Troikaa Pharmaceuticals Philippines, Inc. | DRP-16685 | May 21, 2030 | |
LevexamLevetiracetam | 250 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-13518 | Mar 3, 2028 | |
LevexamLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-13517 | Mar 3, 2028 | |
Leviacet 250Levetiracetam | 250 mg Film-coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Zhejiang Jingxin Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-17799 | Mar 11, 2031 | |
LevidexLevetiracetam | 500 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | Rx | Stallion Laboratories Pvt. Ltd.India | Delex Pharma International, Inc.Importer: Ambica International Corporation | DRP-10907-03 | Dec 23, 2031 | |
LevifarLevetiracetam | 250 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Healer's Lab (Unit II)India | Pharmakon Biotec Inc. | DRP-16435 | Mar 11, 2030 | |
LevinovLevetiracetam | 100 mg/ml Solution for Injection (I.V. Infusion)Type I Clear Glass Vial sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with Green Flip- off Seal Cap x 1's (Box of 1's and 5's) | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-17809 | Mar 12, 2031 | |
LevipamLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's); Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India 174101 | Northmed Pharma and Medical Supplies DistributionImporter: Pharmakon Biotec Inc. | DRP-13517-08 | Mar 3, 2028 | |
LevipilLevetiracetam | 100 mg/mL Concentrate Solution for IV Infusion5 mL (Net Content) Type I clear and colorless glass vial with 20 mm gray bromobutyl rubber stopper and 20 mm aluminum seal with green plastic flip-off cap (Box of 1's) | Rx | Sun Pharmaceutical Medicare LimitedIndia | Sun Pharma Philippines, Inc. | DRP-11418 | May 9, 2028 | |
Levipil 500Levetiracetam | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Sun Pharmaceutical Industries Ltd.India | Sun Pharma Philippines, Inc. | DRP-8661 | May 9, 2027 | |
Levipil 750Levetiracetam | 750 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 50's) | Rx | Sun Pharma Laboratories Ltd.India | Sun Pharma Philippines, Inc. | DRP-8662 | Oct 16, 2028 | |
Levipil XR 1000Levetiracetam | 1 g Extended Release TabletAlu/Alu PVC Cold forming Blister Pack x 6's (Box of 30's) | Rx | Sun Pharmaceutical Industries LimitedIndia | Sun Pharma Philippines, Inc. | DR-XY48320 | Aug 31, 2027 | |
Levipil XR 1500Levetiracetam | 1.5 g Extended Release TabletAlu/Alu PVC Cold forming Blister Pack x 10's (Box of 30's) | Rx | Sun Pharmaceutical Industries LimitedIndia | Sun Pharma Philippines, Inc. | DR-XY48319 | Aug 30, 2027 | |
Levipra 250Levetiracetam | 250 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Unison Laboratories Co., Ltd.Thailand | Justright Healthcare Inc. | DR-XY49529 | Oct 1, 2030 | |
Levipra 500Levetiracetam | 500mg TabletAlu/Alu Blister Pack x 6's (Box of 60's) | Rx | Unison Laboratories Co., Ltd.Thailand | Justright Healthcare Inc. | DR-XY49528 | Oct 1, 2030 | |
LevirtigenLevetiracetam | 100 mg/mL Oral SolutionBoston Round Amber Glass Bottle x 300 mL (Box of 1's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-16898-03 | Aug 11, 2030 | |
LevitLevetiracetam | 500 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 60's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DR-XY46913 | Jun 23, 2030 | |
LevitLevetiracetam | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 60's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-8502 | May 28, 2031 | |
Levit IVLevetiracetam | 100 mg / mL (500 mg / 5 mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Red Bromobutyl Rubber Stopper and Blue Flip-off Cap x 5 mL (Box of 2's, 4's, and 10's) | Rx | Aroma Ilac San. Ltd. StiTurkey | Innogen Pharmaceuticals, Inc.Importer: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac San Ve Tic. A.S. | DRP-10900-07 | Dec 14, 2026 | |
Levit IVLevetiracetam | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)USP Type I glass vial sealed with 20 mm grey rubber stopper and blue aluminum flip-off seal x 5 mL (Box of 1's) | Rx | Aspiro Pharma LimitedIndia | Innogen Pharmaceuticals, Inc.Importer: Camber Pharmaceuticals, Inc. | DRP-9232-02 | Aug 18, 2031 | |
Levitam 1000Levetiracetam | 1 g Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's; Box of 60's) | Rx | Zhejiang Jingxin Pharmaceutical Co. Ltd.China | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc. | DRP-13584-01 | Mar 14, 2028 | |
Levitam 500Levetiracetam | 500 mg Film-Coated TabletAlu/ PVC Blister Pack x 10's (Box of 30's & Box of 60's) | Rx | Zhejiang Jingxin Pharmaceutical Co., Ltd.China | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc. | DRP-13585-01 | Mar 14, 2028 | |
LevitarLevetiracetam | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 30’s, 50’s and 100’s) | Rx | Azarias Pharmaceutical Laboratories.Philippines | N/A | DRP-16434 | Mar 11, 2027 | |
Levitar-SLevetiracetam | 100 mg/mL Oral SolutionBoston Round Amber Glass Bottle x 300 mL (Box of 1's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-16898 | Aug 11, 2030 | |
LevitraLevetiracetam | 1 g Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Micro Labs LimitedIndia | Brown and Burk Phils., Inc. | DR-XY48225 | Jul 26, 2027 | |
LevixamLevetiracetam | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Borosilicate Glass Vial with Gray Rubber Stopper and Aluminum Plastic Overseal Cap x 10 mL (Box of 10’s) | Rx | Hainan Poly Pharm. Co., Ltd.China | Uni-Pharma Phils., Inc.Importer: Ambica International Corporation | DRP-11179-01 | Feb 10, 2032 | |
LevixamLevetiracetam | 500 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Uni-Pharma Phils., Inc.Importer: Ambica International Corporation | DRP-10907-01 | Oct 20, 2037 | |
Levizam 500Levetiracetam | 500mg Film-Coated TabletAlu-Clear PVC/PVDC Blister Pack x 10’s (Box of 10’s, 30's, 60's and 100's) | Rx | Sunglow Lifescience Private LimitedIndia | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-16133-01 | Nov 7, 2029 | |
LevsezurLevetiracetam | 100 mg/mL Oral Solution100 mL and 300 mL Amber Bottle (Box of 1's) | Rx | Novagen Healthcare Private LimitedIndia | Medethix, Inc. | DRP-15069 | Apr 4, 2029 | |
LevtrawellLevetiracetam | 1 g Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4584-03 | Aug 5, 2028 | |
LevtrawellLevetiracetam | 100 mg/mL SyrupAmber Colored PET Bottle x 100 mL (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant II)India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4984-01 | Dec 11, 2028 | |
LevtrawellLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4583-07 | Aug 5, 2028 | |
LevtrazemLevetiracetam | 100 mg/mL Solution For Injection (I.V.)USP Type III clear glass vial with grey butyl rubber stopper and aluminum flip off seal x 5 mL (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Diafarm Inc. | DRP-14900 | Feb 6, 2029 | |
LevtraztamLevetiracetam | 100 mg/mL (500 mg/5 mL) Solution for Injection (I.V. Infusion)USP Type I Clear Glass Ampoule x 5 mL (Box of 5’s) | Rx | Cooper Pharma LimitedIndia | Ambica International Corporation | DRP-19137 | Nov 5, 2031 | |
LezureLevetiracetam | 100mg/mL Oral Solution200 mL Type III amber glass bottle with child-resistant plastic cap x 150 mL + 3 mL-capacity PP oral dosing syringe (Box of 1's) | Rx | Hetero Labs Limited (Unit III)India | Camber Pharmaceuticals, Inc. | DRP-9033 | Aug 20, 2031 | |
LogufenLevetiracetam | 250 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30's); Alu/PVC/PVDC Blister Pack x 2's (Physician's Sample) | Rx | Kusum Healthcare Pvt. Ltd.India | Kusum Healthcare Private Limited Branch Office | DR-XY47555 | Nov 24, 2031 | |
LogufenLevetiracetam | 500 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's Box of 30's; Alu/PVC/PVDC Blister Pack x 2's (as Physician's Sample) | Rx | Kusum Healthcare Pvt. Ltd.India | Kusum Healthcare Private Limited Branch Office | DR-XY47258 | May 18, 2031 | |
Lumark-250Levetiracetam | 250 mg film-coated TabletAlu/Clear PVC blister pack x 10's (Box of 10's) | Rx | The Searle Company LimitedPakistan | Britton Distributions, Inc. | DRP-4906 | Nov 8, 2028 | |
Lumark-500Levetiracetam | 500 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | Rx | The Searle Company LimitedPakistan | Britton Distributions, Inc. | DRP-4647 | Sep 2, 2028 | |
MalcetamLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 90's) | Rx | PharmEvo (Pvt.) Ltd.Pakistan | Malyka International Trading Corp.Importer: Accesspoint International Trading Inc. | DRP-4816-01 | Oct 14, 2028 | |
MasolevLevetiracetam | 100 mg/mL (500 mg/5 mL) Solution for Injection (I.V.)5 mL USP Type I clear glass vial (Box of 1's) | Rx | Mason PharmaIndia | Finstad Inc. | DRP-13867 | May 5, 2028 | |
MASOSAVELevetiracetam | 100 mg/mL (500mg/5mL) Solution for Injection (I.V.)5 mL USP Type I clear glass vial (Box of 1's) | Rx | Mason PharmaIndia. | Savelink Pharma and Trading Co.Importer: Finstad Inc. | DRP-13867-03 | May 5, 2028 | |
MyolevLevetiracetam | 100 mg/mL (500 mg/5 mL) Concentrate for Solution for IV InfusionUSP Type I clear glass vial x 5 mL (net content) with grey bromobutyl rubber stopper, aluminum seal, and blue flip-off cap (Box of 10’s & 25’s) | Rx | Kwality Pharmaceuticals Ltd.India | Seapharma International, Inc.Importer: Pharma-Surrey International, Inc. | DRP-17876-01 | Mar 30, 2031 | |
NeurolevLevetiracetam | 250 mg Film Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | Rx | Micro Labs LimitedIndia | Brtown & Burk Philippines Inc.Importer: Brown & Burk Philippines Inc. | DRP-7249 | Jan 21, 2031 | |
NeurolevLevetiracetam | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30s and 100's) | Rx | Micro Labs LimitedIndia | Zuellig Pharma CorporationImporter: OEP Philippines, Inc. | DRP-7248 | Jun 16, 2031 | |
NoneLevetiracetam | 1 g Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Actimed, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4584-01 | Aug 5, 2028 | |
NoneLevetiracetam | 250 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Actimed, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4585-02 | Aug 5, 2028 | |
NoneLevetiracetam | 250mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | Synmosa Biopharma Philippines Inc.Importer: Medethix, Inc. | DRP-13283-01 | Feb 2, 2028 | |
NoneLevetiracetam | 500 mg Film-Coated TabletAlu/ Clear PVDC Blister Pack x 10's (Box of 60's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen’s Research, Inc. | DR-XY43110 | Dec 19, 2028 | |
NoneLevetiracetam | 500 mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 60's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DR-XY47087 | Oct 20, 2030 | |
NoneLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | — | Reta DrugImporter: Pharmakon Biotec Inc. | DRP-13517-06 | Mar 3, 2028 | |
NoneLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | TGP Pharma Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4583-03 | Aug 5, 2028 | |
NoneLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4583-09 | Aug 5, 2028 | |
NoneLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | PharmEvo (Pvt.) Ltd.Pakistan | Reta DrugImporter: Accesspoint International Trading Inc. | DRP-4816-02 | Oct 14, 2028 | |
NoneLevetiracetam | 500 mg Film-Coated TabletAluminum/PVC/PCTFE Blister Pack x 10 Tablets (Box of 30's) | Rx | Jubilant Generics LimitedIndia | RiteMED PHILS., INC. | DRP-5940 | Jan 22, 2030 | |
NoneLevetiracetam | 750 mg Film-coated TabletAlu/Clear PVC Blister Pack x 10's Box of 50's | Rx | Sun Pharmaceutical Industries Ltd.India | Ritemed Phils., Inc.Importer: Sun Pharma Philippines, Inc. | DRP-8662-01 | May 9, 2027 | |
NovacetamLevetiracetam | 500mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | ACME Formulation Pvt. Ltd.India | Medinova Pharmaceutical, Inc. | DRP-10808 | Nov 25, 2026 | |
Racet-SLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Starpharm, Inc. | DRP-16434-03 | Mar 11, 2027 | |
Rancetam-1000Levetiracetam | 1g Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Hetero Labs Limited (Unit III)India | Camber Pharmaceuticals, Inc. | DRP-6433 | Nov 22, 2030 | |
RaxetacsLevetiracetam | 100 mg/mL (500 mg/5 mL) Concentrate Solution for IV InfusionUSP Type I clear glass vial x 5 mL + grey bromobutyl rubber stopper, aluminum seal and blue flip-off cap (Box of 1's and 10's) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-17211 | Oct 20, 2031 | |
Reflate 500Levetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 60's); Alu/Alu Blister Pack x 10's (Box of 100's) | Rx | XL Laboratories Pvt. Ltd.India | Wisenheimer TradingImporter: Ambica International Corporation | DRP-4852 | Oct 23, 2028 | |
RenaiorLevetiracetam | 100 mg/mL Solution For Injection (IV)Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Yellow Aluminum Flip-off Cap in Plastic Tray x 5 mL (Box of 1's, 5's and 10's) | Rx | Ciron Drugs & PharmaceuticalsIndia | Despina Pharma Inc. | DRP-18383 | Jun 29, 2031 | |
SalvetamLevetiracetam | 100 mg/mL (500 mg/mL) Solution for Injection (I.V.)5 mL USP Type I clear glass vial (Box of 1's) | Rx | Mason PharmaIndia | Salusa Medical Supplies and Pharmaceuticals IncImporter: Finstad Inc. | DRP-13867-02 | May 5, 2028 | |
SeiletamLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13517-04 | Mar 3, 2028 | |
Seiz 500Levetiracetam | 500 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 100's) | Rx | Hetero Labs Limited (Unit III)India | Preventia Healthcare Inc.Importer: Camber Pharmaceuticals, Inc. | DRP-6432-01 | Nov 30, 2027 | |
Seiz 500Levetiracetam | 500 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Preventia Healthcare Inc.Importer: Ambica International Corporation | DRP-10907-02 | Oct 28, 2031 | |
SEIZ OSLevetiracetam | 100 mg/mL Oral Solution200 mL Type III amber glass bottle with child-resistant plastic cap x 150 mL + 3 mL-capacity PP oral dosing syringe (Box of 1's) | Rx | Hetero Labs Limited (Unit III)India | Preventia Healthcare Inc.Importer: Camber Pharmaceuticals, Inc. | DRP-9033-02 | Sep 11, 2031 | |
SezuvinLevetiracetam | 100 mg/mL (500 mg/5 mL) Solution for Injection (I.V.)5 mL USP Type I clear glass vial (Box of 1's) | Rx | Mason PharmaIndia | MDB Pharma TradingImporter: Finstad Inc. | DRP-13867-01 | May 5, 2028 | |
TiracezanLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Triple 888 Medical And Pharma Inc. | DRP-16434-05 | Mar 11, 2027 | |
TroycetamLevetiracetam | 100 mg / mL Concentrate Solution for Injection (IV Infusion)5mL Clear Vial (Ph. Eur. Type I) with 20mm Bromobutyl Rubber Stopper and 20mm White Flip Off Seal (Box of 1's) | Rx | Troikaa Pharmaceuticals LimitedIndia | PSAHM Medpharma TradingImporter: Troikaa Pharmaceuticals Philippiners, Inc. | DRP-16685-01 | May 21, 2030 | |
UnbrandedLevetiracetam | 1 g Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Jubilant Generics LimitedIndia | RITEMED PHILS., INC. | DRP-6169 | Jun 5, 2031 | |
UnbrandedLevetiracetam | 250 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | Rx | Micro Labs LimitedSipcot Complex Hosur -635 126 Tamil Nadu India | Brown & Burk Philippines, Inc.Importer: OEP Philippines, Inc. | DRP-7249-01 | Jan 21, 2031 | |
Vexlev 100Levetiracetam | 100mg/mL Syrup (Grape Flavor)Type III Amber Glass Bottle with Child Resistant Tamper-Evident Screw Cap x 300mL with Oral dosing Syringe (Box of 1's) | Rx | One Pharma Industrial Pharmaceutical Company S.A.Greece | VE Pharma Inc.Trader: Vexxa Lifesciences Limited | DR-XY49496 | Sep 4, 2030 | |
Vexlev 250Levetiracetam | 250 mg Film-Coated TabletAlu-Alu Blister Pack x 10’s (Box of 30's) | Rx | Akums Drugs & Pharmaceuticals Ltd.India | VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd | DRP-7027 | Dec 9, 2028 | |
Vexlev 500Levetiracetam | 500 mg Film-Coated TabletAlu-Alu Blister Pack x 10’s Box of 30’s | Rx | Akums Drugs & Pharmaceuticals Ltd.India | VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd | DRP-XY43069 | Dec 6, 2028 | |
Vexlev IVLevetiracetam | 100 mg/mL (500 mg/5 mL) Concentrated Solution for IV InfusionType I glass vial x 5mL with grey bromobutyl rubber stopper, aluminum seal and orange flip-off cap (Box of 1's) | Rx | Vexxa Lifesciences LimitedHongkong | Ve Pharma Inc. | DR-XY49428 | Jun 27, 2030 | |
XolcetamLevetiracetam | 250 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Xolvemed Pharma IncorporatedImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4585 | Aug 5, 2028 | |
XolvecetamLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Xolvemed Pharma IncorporatedImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4583-10 | Aug 5, 2028 | |
ZeiskonLevetiracetam | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets) | Rx | CONSERN PHARMA LIMITEDIndia | Pharmakon Biotec Inc.Trader: Neer Life Sciences | DRP-14264 | Aug 4, 2028 | |
ZoleviLevetiracetam | 1g Film-Coated tabletAlu/Alu Blister Pack x 10's Box of 60's | Rx | Lek Pharmaceuticals D.D.Slovenia | Natrapharm, Inc.Importer: Sandoz Philippines Corporation | DRP-5280-01 | Apr 23, 2029 | |
ZoleviLevetiracetam | 250 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 60's) | Rx | Lek Pharmaceuticals D.DSlovenia | Natrapharm Inc.Importer: Sandoz Philippines Corporation | DRP-7486-01 | Feb 13, 2029 | |
ZoleviLevetiracetam | 500mg Film-Coated tabletAlu/Alu Blister Pack x 10's (Box of 60's) | Rx | LEK PHARMACEUTICALS D.DSlovenia | Natrapharm, Inc.Importer: Sandoz Philippines Corporation | DRP-7484-01 | Feb 13, 2029 | |
(no brand name)Levetiracetam. | 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | Medethix, Inc. | DRP-16431 | Mar 10, 2030 | |
(no brand name)Levetiracetam | 100 mg/ mL Concentrate for Solution for IV InfusionSP type I glass vial with dark grey bromobutyl rubber stopper and golden yellow flip-off aluminum seal x 5 mL (Box of 1's) | Rx | Mylan Laboratories Limited (Hosur Sterile Facility)India | Viatris Pharmaceuticals, Inc. | DR-XY48845 | Aug 14, 2028 | |
(no brand name)Levetiracetam | 100 mg/mL (500 mg/5 mL) Concentrate Solution For Infusion (IV)Type I Glass Vial sealed with rubber stopper and aluminum with blue flip off cap x 5 mL (Box of 10's) | Rx | Beijing Sciecure Pharmaceutical Co., Ltd.China | Block 20 Pharma Trading | DRP-13122 | Dec 5, 2027 | |
(no brand name)Levetiracetam | 100 mg/mL (500 mg/5 mL) Concentrate Solution for IV Infusion5 mL (net content) in 7.5 mL USP Type I Clear Glass Clear Vial with Bromo Butyl Rubber Plug and Sealed with White Flip-Seal (Box of 1's) | Rx | Skymap Healthcare Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-16820 | Jul 15, 2030 | |
(no brand name)Levetiracetam | 100 mg/mL Concentrate for Solution for Infusion (IV)Type I glass vial x 5 mL (net content), with grey bromobutyl rubber stopper, alumminum seal and orange flip-off cap (Box of 10's) | Rx | Pharmathen SAGreece | Saifen Drugs Philippines Inc. | DR-XY49449 | Jul 15, 2030 | |
(no brand name)Levetiracetam | 100 mg/mL Concentrate For Solution For Iv Infusion5 mL USP Type I Clear Glass Vial (Box of 1's and 10's) | Rx | Gland Pharma LimitedIndia | Trader: Pfizer, Inc. | DRP-46035 | Oct 2, 2027 | |
(no brand name)Levetiracetam | 100 mg/mL Oral Solution (Grape Flavor)Wide-mouth, boston round, amber glass bottle x 60 mL, 125 mL, 150 mL and 300 mL (Box of 1's) | Rx | Lifesquare Laboratories, Inc.Philippines | — | DRP-13070 | Nov 25, 2027 | |
(no brand name)Levetiracetam | 100mg/mL Oral Solution100 mL and 300 mL Amber Bottle (Box of 1's) | Rx | Novagen Healthcare Private LimitedIndia | Medethix, Inc. | DRP-15070 | Apr 4, 2029 | |
(no brand name)Levetiracetam | 250mg Film-Coated TabletAlu/Alu Blister pack x 10's | Rx | — | — | DRP-13284 | Jan 18, 2028 | |
(no brand name)Levetiracetam | 500mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | MedEthix, Inc. | DRP-13282 | Jan 18, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS 250 mg, 500 mg, 750 mg, and 1000 mg film-coated, scored tablets (3) 100 mg/mL solution (3) KEPPRA Tablets 250 mg: blue, oblong-shaped, scored, film-coated, and debossed with "ucb 250" on one side 500 mg: yellow, oblong-shaped, scored, film-coated, and debossed with "ucb 500" on one side 750 mg: orange, oblong-shaped, scored, film-coated, and debossed with "ucb 750" on one side 1000 mg: white, oblong-shaped, scored, film-coated, and debossed with "ucb 1000" on one side KEPPRA Oral Solution 100 mg/mL: a clear, colorless, grape-flavored liquid
Warnings/Precautions
- Behavioral abnormalities including psychotic symptoms, suicidal ideation, irritability, and aggressive behavior have been observed; monitor patients for psychiatric signs and symptoms (5.1)
- Suicidal Behavior and Ideation: Monitor patients for new or worsening depression, suicidal thoughts/behavior, and/or unusual changes in mood or behavior (5.2)
- Monitor for somnolence and fatigue and advise patients not to drive or operate machinery until they have gained sufficient experience on KEPPRA (5.3)
- Serious Dermatological Reactions: Discontinue KEPPRA at the first sign of rash unless clearly not drug related (5.5)
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity: Discontinue if no alternative etiology (5.6)
- Coordination Difficulties: Monitor for ataxia, abnormal gait, and incoordination. Advise patients to not drive or operate machinery until they have gained experience on KEPPRA (5.7)
- Withdrawal Seizures: KEPPRA must be gradually withdrawn (5.8)
5.1 Behavioral Abnormalities and Psychotic Symptoms
5.1 Behavioral Abnormalities and Psychotic Symptoms KEPPRA may cause behavioral abnormalities and psychotic symptoms. Patients treated with KEPPRA should be monitored for psychiatric signs and symptoms. Behavioral abnormalities In clinical studies, 13% of adult KEPPRA-treated patients and 38% of pediatric KEPPRA-treated patients (4 to 16 years of age) compared to 6% and 19% of adult and pediatric placebo-treated patients, experienced non-psychotic behavioral symptoms (reported as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, hyperkinesias, irritability, nervousness, neurosis, and personality disorder).
A randomized double-blind, placebo-controlled study was performed to assess the neurocognitive and behavioral effects of KEPPRA as adjunctive therapy in pediatric patients (4 to 16 years of age). The results from an exploratory analysis indicated a worsening in KEPPRA-treated patients on aggressive behavior (one of eight behavior dimensions) as measured in a standardized and systematic way using a validated instrument, the Achenbach Child Behavior Checklist (CBCL/6-18).
In clinical studies in pediatric patients 1 month to < 4 years of age, irritability was reported in 12% of the KEPPRA-treated patients compared to 0% of placebo-treated patients. In clinical studies, 1.7% of adult KEPPRA-treated patients discontinued treatment due to behavioral adverse reactions, compared to 0.2% of placebo-treated patients.
The treatment dose was reduced in 0.8% of adult KEPPRA-treated patients and in 0.5% of placebo-treated patients. Overall, 11% of KEPPRA-treated pediatric patients experienced behavioral symptoms associated with discontinuation or dose reduction, compared to 6% of placebo-treated patients. Psychotic symptoms In clinical studies, 1% of KEPPRA-treated adult patients, 2% of KEPPRA-treated pediatric patients 4 to 16 years of age, and 17% of KEPPRA-treated pediatric patients 1 month to <4 years of age experienced psychotic symptoms, compared to 0.2%, 2%, and 5% in the corresponding age groups treated with placebo.
In a controlled study that assessed the neurocognitive and behavioral effects of KEPPRA in pediatric patients 4 to 16 years of age, 1.6% of KEPPRA-treated patients experienced paranoia, compared to 0% of placebo-treated patients. In the same study, 3.1% of KEPPRA-treated patients experienced confusional state, compared to 0% of placebo-treated patients [see Use in Specific Populations (8.4)].
In clinical studies, two (0.3%) KEPPRA-treated adult patients were hospitalized and their treatment was discontinued due to psychosis. Both events, reported as psychosis, developed within the first week of treatment and resolved within 1 to 2 weeks following treatment discontinuation. There was no difference between drug and placebo-treated patients in the incidence of the pediatric patients who discontinued treatment due to psychotic and non-psychotic adverse reactions.
5.2 Suicidal Behavior and Ideation
5.2 Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including KEPPRA, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated.
There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed.
Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication.
The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed. Table 2 shows absolute and relative risk by indication for all evaluated AEDs. Table 2: Risk by Indication for Antiepileptic Drugs in the Pooled Analysis Indication Placebo Patients with Events Per 1000 Patients Drug Patients with Events Per 1000 Patients Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients Risk Difference: Additional Drug Patients with Events Per 1000 Patients Epilepsy 1.0 3.4 3.5 2.4 Psychiatric 5.7 8.5 1.5 2.9 Other 1.0 1.8 1.9 0.9 Total 2.4 4.3 1.8 1.9 The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.
Anyone considering prescribing KEPPRA or any other AED must balance the risk of suicidal thoughts or behaviors with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.
Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.
5.3 Somnolence and Fatigue
5.3 Somnolence and Fatigue KEPPRA may cause somnolence and fatigue. Patients should be monitored for these signs and symptoms and advised not to drive or operate machinery until they have gained sufficient experience on KEPPRA to gauge whether it adversely affects their ability to drive or operate machinery. Somnolence In controlled trials of adult patients with epilepsy experiencing partial-onset seizures, 15% of KEPPRA-treated patients reported somnolence, compared to 8% of placebo-treated patients.
There was no clear dose response up to 3000 mg/day. In a study where there was no titration, about 45% of patients receiving 4000 mg/day reported somnolence. The somnolence was considered serious in 0.3% of KEPPRA-treated patients, compared to 0% in the placebo group. About 3% of KEPPRA-treated patients discontinued treatment due to somnolence, compared to 0.7% of placebo-treated patients.
In 1.4% of KEPPRA-treated patients and 0.9% of placebo-treated patients, the dose was reduced, while 0.3% of the KEPPRA-treated patients were hospitalized due to somnolence. Asthenia In controlled clinical studies of adult patients with epilepsy experiencing partial-onset seizures, 15% of KEPPRA-treated patients reported asthenia, compared to 9% of placebo-treated patients.
Treatment was discontinued due to asthenia in 0.8% of KEPPRA-treated patients as compared to 0.5% of placebo-treated patients. In 0.5% of KEPPRA-treated patients and in 0.2% of placebo-treated patients, the dose was reduced due to asthenia. Somnolence and asthenia occurred most frequently within the first 4 weeks of treatment.
In general, the incidences of somnolence and fatigue in the pediatric partial-onset seizure studies, and in pediatric and adult myoclonic and primary generalized tonic-clonic seizure studies were comparable to those of the adult partial-onset seizure studies.
5.4 Anaphylaxis and Angioedema
5.4 Anaphylaxis and Angioedema KEPPRA can cause anaphylaxis or angioedema after the first dose or at any time during treatment. Signs and symptoms in cases reported in the postmarketing setting have included hypotension, hives, rash, respiratory distress, and swelling of the face, lip, mouth, eye, tongue, throat, and feet.
In some reported cases, reactions were life-threatening and required emergency treatment. If a patient develops signs or symptoms of anaphylaxis or angioedema, KEPPRA should be discontinued and the patient should seek immediate medical attention. KEPPRA should be discontinued permanently if a clear alternative etiology for the reaction cannot be established [see Contraindications (4)].
5.5 Serious Dermatological Reactions
5.5 Serious Dermatological Reactions Serious dermatological reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in both pediatric and adult patients treated with KEPPRA. The median time of onset is reported to be 14 to 17 days, but cases have been reported at least four months after initiation of treatment.
Recurrence of the serious skin reactions following rechallenge with KEPPRA has also been reported. KEPPRA should be discontinued at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered.
5.6 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
5.6 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including KEPPRA. These events can be fatal or life-threatening, particularly if diagnosis and treatment do not occur as early as possible.
DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis, sometimes resembling an acute viral infection. Eosinophilia is often present.
Because this disorder is variable in its expression, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately.
KEPPRA should be discontinued if an alternative etiology for the signs or symptoms cannot be established [see Contraindications (4)].
5.7 Coordination Difficulties
5.7 Coordination Difficulties KEPPRA may cause coordination difficulties. In controlled clinical studies in adult patients with partial-onset seizure studies, 3.4% of adult KEPPRA-treated patients experienced coordination difficulties, (reported as either ataxia, abnormal gait, or incoordination) compared to 1.6% of placebo-treated patients.
A total of 0.4% of patients in controlled clinical studies discontinued KEPPRA treatment due to ataxia, compared to 0% of placebo-treated patients. In 0.7% of KEPPRA-treated patients and in 0.2% of placebo-treated patients, the dose was reduced due to coordination difficulties, while one of the KEPPRA-treated patients was hospitalized due to worsening of pre-existing ataxia.
These events occurred most frequently within the first 4 weeks of treatment. Patients should be monitored for these signs and symptoms and advised not to drive or operate machinery until they have gained sufficient experience on KEPPRA to gauge whether it could adversely affect their ability to drive or operate machinery.
5.8 Withdrawal Seizures
5.8 Withdrawal Seizures As with most antiepileptic drugs, KEPPRA should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. If withdrawal is needed because of a serious adverse reaction, rapid discontinuation can be considered.
5.9 Hematologic Abnormalities
5.9 Hematologic Abnormalities KEPPRA can cause hematologic abnormalities. Hematologic abnormalities occurred in clinical trials and included decreases in white blood cell (WBC), neutrophil, and red blood cell (RBC) counts; decreases in hemoglobin and hematocrit; and increases in eosinophil counts. Cases of agranulocytosis, pancytopenia, and thrombocytopenia have been reported in the postmarketing setting.
A complete blood count is recommended in patients experiencing significant weakness, pyrexia, recurrent infections, or coagulation disorders. Partial-Onset Seizures Adults Minor, but statistically significant, decreases compared to placebo in total mean RBC count (0.03 × 106/mm3), mean hemoglobin (0.09 g/dL), and mean hematocrit (0.38%), were seen in KEPPRA-treated patients in controlled trials.
A total of 3.2% of KEPPRA-treated and 1.8% of placebo-treated patients had at least one possibly significant (≤2.8 × 10 9 /L) decreased WBC, and 2.4% of KEPPRA-treated and 1.4% of placebo-treated patients had at least one possibly significant (≤1.0 × 10 9 /L) decreased neutrophil count. Of the KEPPRA-treated patients with a low neutrophil count, all but one rose towards or to baseline with continued treatment.
No patient was discontinued secondary to low neutrophil counts. Pediatric Patients 4 Years to < 16 Years Statistically significant decreases in WBC and neutrophil counts were seen in KEPPRA-treated patients as compared to placebo. The mean decreases from baseline in the KEPPRA-treated group were -0.4 × 10 9 /L and -0.3 × 10 9 /L, respectively, whereas there were small increases in the placebo group.
Mean relative lymphocyte counts increased by 1.7% in KEPPRA-treated patients, compared to a decrease of 4% in placebo patients (statistically significant). In the controlled trial, more KEPPRA-treated patients had a possibly clinically significant abnormally low WBC value (3% of KEPPRA-treated patients versus 0% of placebo-treated patients), however, there was no apparent difference between treatment groups with respect to neutrophil count (5% of KEPPRA-treated patients versus 4.2% of placebo-treated patients).
No patient was discontinued secondary to low WBC or neutrophil counts. In the controlled cognitive and neuropsychological safety study, 5 patients (8.6%) in the KEPPRA-treated group and two patients (6.1%) in the placebo-treated group had high eosinophil count values that were possibly clinically significant (≥10% or ≥0.7 × 10 9 /L).
5.10 Increase in Blood Pressure
5.10 Increase in Blood Pressure In a randomized, placebo-controlled study in patients 1 month to <4 years of age, a significantly higher risk of increased diastolic blood pressure was observed in the KEPPRA-treated patients (17%), compared to the placebo-treated patients (2%). There was no overall difference in mean diastolic blood pressure between the treatment groups.
This disparity between the KEPPRA and placebo treatment groups was not observed in the studies of older children or in adults. Monitor patients 1 month to <4 years of age for increases in diastolic blood pressure.
5.11 Seizure Control During Pregnancy
5.11 Seizure Control During Pregnancy Physiological changes may gradually decrease plasma levels of levetiracetam throughout pregnancy. This decrease is more pronounced during the third trimester. It is recommended that patients be monitored carefully during pregnancy. Close monitoring should continue through the postpartum period especially if the dose was changed during pregnancy.
Adverse reactions
Common
- Somnolence, asthenia, dizziness, infection (adults)
- Children: fatigue, aggression, nasal congestion, decreased appetite, irritability
Serious
- Behavioral abnormalities, psychotic symptoms, suicidal ideation
- Somnolence and coordination difficulties
- Anaphylaxis, angioedema
- Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS
- Withdrawal seizures if stopped abruptly
- Hematologic abnormalities
- The following adverse reactions are discussed in more details in other sections of labeling: Behavior Abnormalities and Psychotic Symptoms [see Warnings and Precautions (5.1)] Suicidal Behavior and Ideation [see Warnings and Precautions (5.2)] Somnolence and Fatigue [see Warnings and Precautions (5.3)] Anaphylaxis and Angioedema [see Warnings and Precautions (5.4)] Serious Dermatological Reactions [see Warnings and Precautions (5.5)] Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity [see Warnings and Precautions (5.6)] Coordination Difficulties [see Warnings and Precautions (5.7)] Hematologic Abnormalities [see Warnings and Precautions (5.9)] Increase in Blood Pressure [see Warnings and Precautions (5.10)] Most common adverse reactions (incidence ≥ 5% more than placebo) include: Adult patients: somnolence, asthenia, infection and dizziness (6.1)
- Pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact UCB, Inc. at 1-844-599-2273 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Partial-Onset Seizures Adults In controlled clinical studies in adults with partial-onset seizures [see Clinical Studies (14.1)], the most common adverse reactions in patients receiving KEPPRA in combination with other AEDs, for events with rates greater than placebo, were somnolence, asthenia, infection, and dizziness.
Of the most common adverse reactions in adults experiencing partial-onset seizures, asthenia, somnolence, and dizziness occurred predominantly during the first 4 weeks of treatment with KEPPRA. Table 3 lists adverse reactions that occurred in at least 1% of adult epilepsy patients receiving KEPPRA in placebo-controlled studies and were numerically more common than in patients treated with placebo.
In these studies, either KEPPRA or placebo was added to concurrent AED therapy. Table 3: Adverse Reactions in Pooled Placebo-Controlled, Adjunctive Studies in Adults Experiencing Partial-Onset Seizures KEPPRA (N=769) % Placebo (N=439) % Asthenia 15 9 Somnolence 15 8 Headache 14 13 Infection 13 8 Dizziness 9 4 Pain 7 6 Pharyngitis 6 4 Depression 4 2 Nervousness 4 2 Rhinitis 4 3 Anorexia 3 2 Ataxia 3 1 Vertigo 3 1 Amnesia 2 1 Anxiety 2 1 Cough Increased 2 1 Diplopia 2 1 Emotional Lability 2 0 Hostility 2 1 Paresthesia 2 1 Sinusitis 2 1 In controlled adult clinical studies, 15% of patients receiving KEPPRA and 12% receiving placebo either discontinued or had a dose reduction as a result of an adverse reaction.
Table 4 lists the most common (>1%) adverse reactions that resulted in discontinuation or dose reduction and that occurred more frequently in KEPPRA-treated patients than in placebo-treated patients. Table 4: Adverse Reactions that Resulted in Discontinuation or Dose Reduction in Placebo-Controlled Studies in Adult Patients Experiencing Partial-Onset Seizures Adverse Reaction KEPPRA (N=769) % Placebo (N=439) % Somnolence 4 2 Dizziness 1 0 Pediatric Patients 4 Years to <16 Years The adverse reaction data presented below was obtained from a pooled analysis of two controlled pediatric clinical studies in pediatric patients 4 to 16 years of age with partial-onset seizures.
The most common adverse reactions in pediatric patients receiving KEPPRA in combination with other AEDs, for events with rates greater than placebo, were fatigue, aggression, nasal congestion, decreased appetite, and irritability. Table 5 lists adverse reactions from the pooled pediatric controlled studies (4 to 16 years of age) that occurred in at least 2% of pediatric KEPPRA-treated patients and were numerically more common than in pediatric patients treated with placebo.
In these studies, either KEPPRA or placebo was added to concurrent AED therapy. Table 5: Adverse Reactions in Pooled Placebo-Controlled, Adjunctive Studies in Pediatric Patients Ages 4 to 16 Years Experiencing Partial-Onset Seizures KEPPRA (N=165) % Placebo (N=131) % Headache 19 15 Nasopharyngitis 15 12 Vomiting 15 12 Somnolence 13 9 Fatigue 11 5 Aggression 10 5 Cough 9 5 Nasal Congestion 9 2 Upper Abdominal Pain 9 8 Decreased Appetite 8 2 Abnormal Behavior 7 4 Dizziness 7 5 Irritability 7 1 Pharyngolaryngeal Pain 7 4 Diarrhea 6 2 Lethargy 6 5 Insomnia 5 3 Agitation 4 1 Anorexia 4 3 Head Injury 4 0 Altered Mood 3 1 Constipation 3 1 Contusion 3 1 Depression 3 1 Fall 3 2 Influenza 3 1 Affect Lability 2 1 Anxiety 2 1 Arthralgia 2 0 Confusional State 2 0 Conjunctivitis 2 0 Ear Pain 2 1 Gastroenteritis 2 0 Joint Sprain 2 1 Mood Swings 2 1 Neck Pain 2 1 Rhinitis 2 0 Sedation 2 1 In the controlled pooled pediatric clinical studies in patients 4-16 years of age, 7% of patients receiving KEPPRA and 9% receiving placebo discontinued as a result of an adverse reaction.
Pediatric Patients 1 Month to < 4 Years In the 7-day, controlled pediatric clinical study in children 1 month to less than 4 years of age with partial-onset seizures, the most common adverse reactions in patients receiving KEPPRA in combination with other AEDs, for events with rates greater than placebo, were somnolence and irritability. Because of the shorter exposure period, incidences of adverse reactions are expected to be lower than in other pediatric studies in older patients.
Therefore, other controlled pediatric data, presented above, should also be considered to apply to this age group. Table 6 lists adverse reactions that occurred in at least 5% of pediatric epilepsy patients (ages 1 month to < 4 years) treated with KEPPRA in the placebo-controlled study and were numerically more common than in patients treated with placebo.
In this study, either KEPPRA or placebo was added to concurrent AED therapy. Table 6: Adverse Reactions in a Placebo-Controlled, Adjunctive Study in Pediatric Patients Ages 1 Month to < 4 Years Experiencing Partial-Onset Seizures KEPPRA (N=60) % Placebo (N=56) % Somnolence 13 2 Irritability 12 0 In the 7-day controlled pediatric clinical study in patients 1 month to < 4 years of age, 3% of patients receiving KEPPRA and 2% receiving placebo either discontinued or had a dose reduction as a result of an adverse reaction.
There was no adverse reaction that resulted in discontinuation for more than one patient. Myoclonic Seizures Although the pattern of adverse reactions in this study seems somewhat different from that seen in patients with partial-onset seizures, this is likely due to the much smaller number of patients in this study compared to partial seizure studies.
The adverse reaction pattern for patients with JME is expected to be essentially the same as for patients with partial seizures. In the controlled clinical study in patients 12 years of age and older with myoclonic seizures [see Clinical Studies (14.2)], the most common adverse reactions in patients receiving KEPPRA in combination with other AEDs, for events with rates greater than placebo, were somnolence, neck pain, and pharyngitis.
Table 7 lists adverse reactions that occurred in at least 5% of juvenile myoclonic epilepsy patients experiencing myoclonic seizures treated with KEPPRA and were numerically more common than in patients treated with placebo. In this study, either KEPPRA or placebo was added to concurrent AED therapy. Table 7: Adverse Reactions in a Placebo-Controlled, Adjunctive Study in Patients 12 Years of Age and Older with Myoclonic Seizures KEPPRA (N=60) % Placebo (N=60) % Somnolence 12 2 Neck pain 8 2 Pharyngitis 7 0 Depression 5 2 Influenza 5 2 Vertigo 5 3 In the placebo-controlled study, 8% of patients receiving KEPPRA and 2% receiving placebo either discontinued or had a dose reduction as a result of an adverse reaction.
The adverse reactions that led to discontinuation or dose reduction and that occurred more frequently in KEPPRA-treated patients than in placebo-treated patients are presented in Table 8. Table 8: Adverse Reactions that Resulted in Discontinuation or Dose Reduction in a Placebo-Controlled Study in Patients with Juvenile Myoclonic Epilepsy Adverse Reaction KEPPRA (N=60) % Placebo (N=60) % Anxiety 3 2 Depressed mood 2 0 Depression 2 0 Diplopia 2 0 Hypersomnia 2 0 Insomnia 2 0 Irritability 2 0 Nervousness 2 0 Somnolence 2 0 Primary Generalized Tonic-Clonic Seizures Although the pattern of adverse reactions in this study seems somewhat different from that seen in patients with partial-onset seizures, this is likely due to the much smaller number of patients in this study compared to partial seizure studies.
The adverse reaction pattern for patients with primary generalized tonic-clonic (PGTC) seizures is expected to be essentially the same as for patients with partial seizures. In the controlled clinical study that included patients 4 years of age and older with PGTC seizures [see Clinical Studies (14.3)], the most common adverse reaction in patients receiving KEPPRA in combination with other AEDs, for events with rates greater than placebo, was nasopharyngitis.
Table 9 lists adverse reactions that occurred in at least 5% of idiopathic generalized epilepsy patients experiencing PGTC seizures treated with KEPPRA and were numerically more common than in patients treated with placebo. In this study, either KEPPRA or placebo was added to concurrent AED therapy. Table 9: Adverse Reactions in a Placebo-Controlled, Adjunctive Study in Patients 4 Years of Age and Older with PGTC Seizures KEPPRA (N=79) % Placebo (N=84) % Nasopharyngitis 14 5 Fatigue 10 8 Diarrhea 8 7 Irritability 6 2 Mood swings 5 1 In the placebo-controlled study, 5% of patients receiving KEPPRA and 8% receiving placebo either discontinued or had a dose reduction during the treatment period as a result of an adverse reaction.
This study was too small to adequately characterize the adverse reactions that could be expected to result in discontinuation of treatment in this population. It is expected that the adverse reactions that would lead to discontinuation in this population would be similar to those resulting in discontinuation in other epilepsy trials (see tables 4 and 8).
In addition, the following adverse reactions were seen in other controlled adult studies of KEPPRA: balance disorder, disturbance in attention, eczema, memory impairment, myalgia, and blurred vision. Comparison of Gender, Age and Race The overall adverse reaction profile of KEPPRA was similar between females and males. There are insufficient data to support a statement regarding the distribution of adverse reactions by age and race.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of KEPPRA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been reported in patients receiving marketed KEPPRA worldwide.
The listing is alphabetized: abnormal liver function test, acute kidney injury, anaphylaxis, angioedema, agranulocytosis, choreoathetosis, drug reaction with eosinophilia and systemic symptoms (DRESS), dyskinesia, erythema multiforme, hepatic failure, hepatitis, hyponatremia, muscular weakness, obsessive-compulsive disorders (OCD), pancreatitis, pancytopenia (with bone marrow suppression identified in some of these cases), panic attack, thrombocytopenia, weight loss, and worsening of seizures including in patients with SCN8A mutations. Alopecia has been reported with KEPPRA use; recovery was observed in majority of cases where KEPPRA was discontinued.
Adverse reaction frequency tables (US label) US FDA label
| KEPPRA (N=769) % | Placebo (N=439) % | |
|---|---|---|
| Asthenia | 15 | 9 |
| Somnolence | 15 | 8 |
| Headache | 14 | 13 |
| Infection | 13 | 8 |
| Dizziness | 9 | 4 |
| Pain | 7 | 6 |
| Pharyngitis | 6 | 4 |
| Depression | 4 | 2 |
| Nervousness | 4 | 2 |
| Rhinitis | 4 | 3 |
| Anorexia | 3 | 2 |
| Ataxia | 3 | 1 |
| Vertigo | 3 | 1 |
| Amnesia | 2 | 1 |
| Anxiety | 2 | 1 |
| Cough Increased | 2 | 1 |
| Diplopia | 2 | 1 |
| Emotional Lability | 2 | 0 |
| Hostility | 2 | 1 |
| Paresthesia | 2 | 1 |
| Sinusitis | 2 | 1 |
| Adverse Reaction | KEPPRA (N=769) % | Placebo (N=439) % |
|---|---|---|
| Somnolence | 4 | 2 |
| Dizziness | 1 | 0 |
| KEPPRA (N=165) % | Placebo (N=131) % | |
|---|---|---|
| Headache | 19 | 15 |
| Nasopharyngitis | 15 | 12 |
| Vomiting | 15 | 12 |
| Somnolence | 13 | 9 |
| Fatigue | 11 | 5 |
| Aggression | 10 | 5 |
| Cough | 9 | 5 |
| Nasal Congestion | 9 | 2 |
| Upper Abdominal Pain | 9 | 8 |
| Decreased Appetite | 8 | 2 |
| Abnormal Behavior | 7 | 4 |
| Dizziness | 7 | 5 |
| Irritability | 7 | 1 |
| Pharyngolaryngeal Pain | 7 | 4 |
| Diarrhea | 6 | 2 |
| Lethargy | 6 | 5 |
| Insomnia | 5 | 3 |
| Agitation | 4 | 1 |
| Anorexia | 4 | 3 |
| Head Injury | 4 | 0 |
| Altered Mood | 3 | 1 |
| Constipation | 3 | 1 |
| Contusion | 3 | 1 |
| Depression | 3 | 1 |
| Fall | 3 | 2 |
| Influenza | 3 | 1 |
| Affect Lability | 2 | 1 |
| Anxiety | 2 | 1 |
| Arthralgia | 2 | 0 |
| Confusional State | 2 | 0 |
| Conjunctivitis | 2 | 0 |
| Ear Pain | 2 | 1 |
| Gastroenteritis | 2 | 0 |
| Joint Sprain | 2 | 1 |
| Mood Swings | 2 | 1 |
| Neck Pain | 2 | 1 |
| Rhinitis | 2 | 0 |
| Sedation | 2 | 1 |
| KEPPRA (N=60) % | Placebo (N=56) % | |
|---|---|---|
| Somnolence | 13 | 2 |
| Irritability | 12 | 0 |
| KEPPRA (N=60) % | Placebo (N=60) % | |
|---|---|---|
| Somnolence | 12 | 2 |
| Neck pain | 8 | 2 |
| Pharyngitis | 7 | 0 |
| Depression | 5 | 2 |
| Influenza | 5 | 2 |
| Vertigo | 5 | 3 |
| Adverse Reaction | KEPPRA (N=60) % | Placebo (N=60) % |
|---|---|---|
| Anxiety | 3 | 2 |
| Depressed mood | 2 | 0 |
| Depression | 2 | 0 |
| Diplopia | 2 | 0 |
| Hypersomnia | 2 | 0 |
| Insomnia | 2 | 0 |
| Irritability | 2 | 0 |
| Nervousness | 2 | 0 |
| Somnolence | 2 | 0 |
| KEPPRA (N=79) % | Placebo (N=84) % | |
|---|---|---|
| Nasopharyngitis | 14 | 5 |
| Fatigue | 10 | 8 |
| Diarrhea | 8 | 7 |
| Irritability | 6 | 2 |
| Mood swings | 5 | 1 |
Monitoring parameters
- Kidney function (CrCl) to set the dose. Seizure control. Behavioral changes, mood, suicidal thinking; somnolence and coordination problems. Avoid abrupt withdrawal. Kidney
- Creatinine clearance for dosing
- Mood and behavior
- Seizure control
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), including KEPPRA, during pregnancy. Encourage women who are taking KEPPRA during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) pregnancy registry by calling 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/.
Risk Summary Prolonged experience with KEPPRA in pregnant women has not identified a drug-associated risk of major birth defects or miscarriage, based on published literature, which includes data from pregnancy registries and reflects experience over two decades [see Human Data]. In animal studies, levetiracetam produced developmental toxicity (increased embryofetal and offspring mortality, increased incidences of fetal structural abnormalities, decreased embryofetal and offspring growth, neurobehavioral alterations in offspring) at doses similar to human therapeutic doses [see Animal Data].
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Clinical Considerations Levetiracetam blood levels may decrease during pregnancy [see Warnings and Precautions (5.11)].
Physiological changes during pregnancy may affect levetiracetam concentration. Decrease in levetiracetam plasma concentrations has been observed during pregnancy. This decrease is more pronounced during the third trimester. Dose adjustments may be necessary to maintain clinical response. Data Human Data While available studies cannot definitively establish the absence of risk, data from the published literature and pregnancy registries have not established an association with levetiracetam use during pregnancy and major birth defects or miscarriage.
Animal Data When levetiracetam (0, 400, 1200, or 3600 mg/kg/day) was administered orally to pregnant rats during the period of organogenesis, reduced fetal weights and increased incidence of fetal skeletal variations were observed at the highest dose tested. There was no evidence of maternal toxicity. The no-effect dose for adverse effects on embryofetal developmental in rats (1200 mg/kg/day) is approximately 4 times the maximum recommended human dose (MRHD) of 3000 mg on a body surface area (mg/m 2) basis.
Oral administration of levetiracetam (0, 200, 600, or 1800 mg/kg/day) to pregnant rabbits during the period of organogenesis resulted in increased embryofetal mortality and incidence of fetal skeletal variations at the mid and high dose and decreased fetal weights and increased incidence of fetal malformations at the high dose, which was associated with maternal toxicity. The no-effect dose for adverse effects on embryofetal development in rabbits (200 mg/kg/day) is approximately equivalent to the MRHD on a mg/m 2 basis.
Oral administration of levetiracetam (0, 70, 350, or 1800 mg/kg/day) to female rats throughout pregnancy and lactation led to an increased incidence of fetal skeletal variations, reduced fetal body weight, and decreased growth in offspring at the mid and high doses and increased pup mortality and neurobehavioral alterations in offspring at the highest dose tested. There was no evidence of maternal toxicity.
The no-effect dose for adverse effects on pre- and postnatal development in rats (70 mg/kg/day) is less than the MRHD on a mg/m 2 basis. Oral administration of levetiracetam to rats during the latter part of gestation and throughout lactation produced no adverse developmental or maternal effects at doses of up to 1800 mg/kg/day (6 times the MRHD on a mg/m 2 basis).
Mechanism of action
12.1 Mechanism of Action The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle exocytosis.
Although the molecular significance of levetiracetam binding to SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice. These findings suggest that the interaction of levetiracetam with the SV2A protein may contribute to the antiepileptic mechanism of action of the drug.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Effects on QTc Interval The effect of KEPPRA on QTc prolongation was evaluated in a randomized, double-blind, positive-controlled (moxifloxacin 400 mg) and placebo-controlled crossover study of KEPPRA (1000 mg or 5000 mg) in 52 healthy subjects. The upper bound of the 90% confidence interval for the largest placebo-adjusted, baseline-corrected QTc was below 10 milliseconds. Therefore, there was no evidence of significant QTc prolongation in this study.
Pharmacokinetics
Key PK parameters
| Bioavailability | 100% |
|---|---|
| Time to peak | About 1 hour |
| Half-life | 7 ± 1 hours |
| Half-life in kidney failure (ESKD) kidney | Prolonged; total clearance 70% lower in anuric ESRD (label) |
| Protein binding | Under 10% |
| Metabolism (CYP, transporters) | Enzymatic hydrolysis (not CYP) to inactive ucb L057 |
| Active metabolites | None |
| Renal excretion kidney | 66% unchanged in urine |
| Dialyzability kidney | Yes (about 50% in 4 hours; label) |
Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration.
Levetiracetam is eliminated from the systemic circulation by renal excretion as unchanged drug which represents 66% of administered dose.
The total body clearance is 0.96 mL/min/kg and the renal clearance is 0.6 mL/min/kg.
The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption.
The metabolite ucb L057 is excreted by glomerular filtration and active tubular secretion with a renal clearance of 4 mL/min/kg.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics The pharmacokinetics of levetiracetam are similar when used as monotherapy or as adjunctive therapy for the treatment of partial-onset seizures. Absorption and Distribution Absorption of levetiracetam is rapid, with peak plasma concentrations occurring in about an hour following oral administration in fasted subjects.
The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption. Food does not affect the extent of absorption of levetiracetam but it decreases C max by 20% and delays T max by 1.5 hours. The pharmacokinetics of levetiracetam are linear over the dose range of 500-5000 mg.
Steady state is achieved after 2 days of multiple twice-daily dosing. Levetiracetam and its major metabolite are less than 10% bound to plasma proteins; clinically significant interactions with other drugs through competition for protein binding sites are therefore unlikely. Metabolism Levetiracetam is not extensively metabolized in humans.
The major metabolic pathway is the enzymatic hydrolysis of the acetamide group, which produces the carboxylic acid metabolite, ucb L057 (24% of dose) and is not dependent on any liver cytochrome P450 isoenzymes. The major metabolite is inactive in animal seizure models. Two minor metabolites were identified as the product of hydroxylation of the 2-oxo-pyrrolidine ring (2% of dose) and opening of the 2-oxo-pyrrolidine ring in position 5 (1% of dose).
There is no enantiomeric interconversion of levetiracetam or its major metabolite. Elimination Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration. Levetiracetam is eliminated from the systemic circulation by renal excretion as unchanged drug which represents 66% of administered dose.
The total body clearance is 0.96 mL/min/kg and the renal clearance is 0.6 mL/min/kg. The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption. The metabolite ucb L057 is excreted by glomerular filtration and active tubular secretion with a renal clearance of 4 mL/min/kg. Levetiracetam elimination is correlated to creatinine clearance.
Levetiracetam clearance is reduced in patients with renal impairment [see Use in Specific Populations (8.6) and Dosage and Administration (2.5)]. Specific Populations Elderly Pharmacokinetics of levetiracetam were evaluated in 16 elderly subjects (age 61-88 years) with creatinine clearance ranging from 30 to 74 mL/min. Following oral administration of twice-daily dosing for 10 days, total body clearance decreased by 38% and the half-life was 2.5 hours longer in the elderly compared to healthy adults.
This is most likely due to the decrease in renal function in these subjects. Pediatric Patients Pharmacokinetics of levetiracetam were evaluated in 24 pediatric patients (age 6-12 years) after single dose (20 mg/kg). The body weight adjusted apparent clearance of levetiracetam was approximately 40% higher than in adults.
A repeat dose pharmacokinetic study was conducted in pediatric patients (age 4-12 years) at doses of 20 mg/kg/day, 40 mg/kg/day, and 60 mg/kg/day. The evaluation of the pharmacokinetic profile of levetiracetam and its metabolite (ucb L057) in 14 pediatric patients demonstrated rapid absorption of levetiracetam at all doses with a T max of about 1 hour and a t 1/2 of 5 hours across the three dosing levels.
The pharmacokinetics of levetiracetam in children was linear between 20 to 60 mg/kg/day. The potential interaction of levetiracetam with other AEDs was also evaluated in these patients. Levetiracetam had no significant effect on the plasma concentrations of carbamazepine, valproic acid, topiramate or lamotrigine. However, there was about a 22% increase of apparent clearance of levetiracetam when it was co-administered with an enzyme-inducing AED (e.g. carbamazepine).
Following single dose administration (20 mg/kg) of a 10% oral solution to children with epilepsy (1 month to < 4 years), levetiracetam was rapidly absorbed and peak plasma concentrations were observed approximately 1 hour after dosing. The pharmacokinetic results indicated that half-life was shorter (5.3 h) than for adults (7.2 h) and apparent clearance was faster (1.5 mL/min/kg) than for adults (0.96 mL/min/kg).
Population pharmacokinetic analysis showed that body weight was significantly correlated to the clearance of levetiracetam in pediatric patients; clearance increased with an increase in body weight. Pediatric Patients with Obesity A population PK analysis of levetiracetam was conducted in 164 obese and non-obese pediatric patients 2 to <18 years of age with median (range) weight 39.2 (11.3-134) kg to evaluate the potential impact of obesity on plasma levetiracetam exposures.
Obesity was defined as BMI ≥95th percentile for age and sex based on CDC 2000 growth chart recommendations. Simulations were conducted for obese and non-obese pediatric patients ages 4 to <16 years. When the recommended tablet dose is administered to pediatric patients weighing < 40 kg, obese pediatric patients have 27% higher median C max,ss and 19% higher median C min,ss compared to non-obese patients.
When the recommended tablet dose is administered to pediatric patients weighing ≥ 40 kg, obese pediatric patients have 10-11% lower median C max,ss and 2% lower median C min,ss compared to non-obese patients. When the recommended oral solution dose is administered to pediatric patients across the full weight range, obese pediatric patients have 25% higher median C max,ss and 41% higher median C min,ss compared to non-obese pediatric patients.
However, differences in exposures between obese and non-obese pediatric patients are not expected to be clinically meaningful because the recommended dose titration at initiation of levetiracetam therapy would establish an appropriate dose for each individual patient. Pregnancy Levetiracetam levels may decrease during pregnancy [see Warnings and Precautions (5.11) and Use in Specific Populations (8.1)].
Gender Levetiracetam C max and AUC were 20% higher in women (N=11) compared to men (N=12). However, clearances adjusted for body weight were comparable. Race Formal pharmacokinetic studies of the effects of race have not been conducted. Cross-study comparisons involving Caucasians (N=12) and Asians (N=12), however, show that pharmacokinetics of levetiracetam were comparable between the two races.
Because levetiracetam is primarily renally excreted and there are no important racial differences in creatinine clearance, pharmacokinetic differences due to race are not expected. Renal Impairment The disposition of levetiracetam was studied in adult subjects with varying degrees of renal function. Total body clearance of levetiracetam is reduced in patients with impaired renal function by 40% in the mild group (CLcr = 50-80 mL/min), 50% in the moderate group (CLcr = 30-50 mL/min) and 60% in the severe renal impairment group (CLcr <30 mL/min).
Clearance of levetiracetam is correlated with creatinine clearance. In anuric (end stage renal disease) patients, the total body clearance decreased 70% compared to normal subjects (CLcr >80 mL/min). Approximately 50% of the pool of levetiracetam in the body is removed during a standard 4- hour hemodialysis procedure [see Dosage and Administration (2.5)].
Hepatic Impairment In subjects with mild (Child-Pugh A) to moderate (Child-Pugh B) hepatic impairment, the pharmacokinetics of levetiracetam were unchanged. In patients with severe hepatic impairment (Child-Pugh C), total body clearance was 50% that of normal subjects, but decreased renal clearance accounted for most of the decrease.
No dose adjustment is needed for patients with hepatic impairment. Drug Interactions In vitro data on metabolic interactions indicate that levetiracetam is unlikely to produce, or be subject to, pharmacokinetic interactions. Levetiracetam and its major metabolite, at concentrations well above C max levels achieved within the therapeutic dose range, are neither inhibitors of, nor high affinity substrates for, human liver cytochrome P450 isoforms, epoxide hydrolase or UDP-glucuronidation enzymes.
In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid. Potential pharmacokinetic interactions of or with levetiracetam were assessed in clinical pharmacokinetic studies (phenytoin, valproate, warfarin, digoxin, oral contraceptive, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
Phenytoin KEPPRA (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy. Pharmacokinetics of levetiracetam were also not affected by phenytoin. Valproate KEPPRA (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers. Valproate 500 mg twice daily did not modify the rate or extent of levetiracetam absorption or its plasma clearance or urinary excretion.
There also was no effect on exposure to and the excretion of the primary metabolite, ucb L057. Other Antiepileptic Drugs Potential drug interactions between KEPPRA and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam. Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.
Dose adjustment is not recommended. Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or lamotrigine. Oral Contraceptives KEPPRA (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.
Coadministration of this oral contraceptive did not influence the pharmacokinetics of levetiracetam. Digoxin KEPPRA (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day. Coadministration of digoxin did not influence the pharmacokinetics of levetiracetam.
Warfarin KEPPRA (1000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin. Prothrombin time was not affected by levetiracetam. Coadministration of warfarin did not affect the pharmacokinetics of levetiracetam. Probenecid Probenecid, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of levetiracetam 1000 mg twice daily.
C ss max of the metabolite, ucb L057, was approximately doubled in the presence of probenecid while the fraction of drug excreted unchanged in the urine remained the same. Renal clearance of ucb L057 in the presence of probenecid decreased 60%, probably related to competitive inhibition of tubular secretion of ucb L057.
The effect of KEPPRA on probenecid was not studied.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Levetiracetam 1 g Film coated tablet | ₱22.45–₱38.00Reference ₱22.45 | per tablet | DPRI procurement range |
| Levetiracetam 100 mg/mL, 300 mL Bottle | ₱1,315.00–₱1,922.98Reference ₱1,315.00 | per bottle | DPRI procurement range |
| Levetiracetam 250 mg Film coated tablet | ₱8.75–₱22.00Reference ₱11.76 | per tablet | DPRI procurement range |
| Levetiracetam 500 mg Film coated tablet | ₱11.50–₱23.50Reference ₱16.38 | per tablet | DPRI procurement range |
| Levetiracetam 500 mg/5 mL Vial | ₱1,200.00–₱2,348.00Reference ₱1,734.00 | per vial | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Levetiracetam |
| PNF listing | Oral: 250 mg, 500 mg, 750 mg, and 1 g film coated tablet |
| PNF listing | Inj.: 500 mg/5 mL (100 mg/mL) concentrate solution for IV infusion, 5 mL vial |
| PNF listing | Solution: 100 mg/mL oral solution, 100 mL and 300 mL bottle |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Keppra · UCB, Inc. [US FDA-approved label, version 36, January 28, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ca9df05-a506-4ec8-a4fe-320f1219ab21
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- UCB, Inc. (2026). KEPPRA (levetiracetam) tablets and oral solution [Prescribing information; US FDA-approved label, NDA021505, set ID 3ca9df05-a506-4ec8-a4fe-320f1219ab21, version effective January 28, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ca9df05-a506-4ec8-a4fe-320f1219ab21
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .
